HRP20100060A2 - 9-substituted monocycline compounds - Google Patents
9-substituted monocycline compounds Download PDFInfo
- Publication number
- HRP20100060A2 HRP20100060A2 HR20100060A HRP20100060A HRP20100060A2 HR P20100060 A2 HRP20100060 A2 HR P20100060A2 HR 20100060 A HR20100060 A HR 20100060A HR P20100060 A HRP20100060 A HR P20100060A HR P20100060 A2 HRP20100060 A2 HR P20100060A2
- Authority
- HR
- Croatia
- Prior art keywords
- minocycline
- group
- compound
- alkyl
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 70
- -1 tetracycline compounds Chemical class 0.000 claims abstract description 301
- 229960004023 minocycline Drugs 0.000 claims abstract description 219
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 8
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims abstract 51
- 125000000217 alkyl group Chemical group 0.000 claims description 110
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 125000003342 alkenyl group Chemical group 0.000 claims description 70
- 125000000304 alkynyl group Chemical group 0.000 claims description 65
- 125000001424 substituent group Chemical group 0.000 claims description 60
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 39
- 125000004414 alkyl thio group Chemical group 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- 125000003282 alkyl amino group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 26
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 24
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 23
- 150000002431 hydrogen Chemical group 0.000 claims description 22
- 150000007942 carboxylates Chemical class 0.000 claims description 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 20
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 20
- 239000000651 prodrug Chemical group 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 19
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 18
- 229910019142 PO4 Inorganic materials 0.000 claims description 17
- 125000004442 acylamino group Chemical group 0.000 claims description 17
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 17
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 16
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 16
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims description 15
- 125000005110 aryl thio group Chemical group 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 claims description 10
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 8
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000005059 halophenyl group Chemical group 0.000 claims description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 6
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 6
- 125000003435 aroyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 4
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 4
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical group CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 claims description 4
- 125000005179 haloacetyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical group CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 4
- 229940072172 tetracycline antibiotic Drugs 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000006248 tosyl amino group Chemical group [H]N(*)S(=O)(=O)C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 3
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005841 biaryl group Chemical group 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 abstract description 73
- 235000019364 tetracycline Nutrition 0.000 abstract description 73
- 229960002180 tetracycline Drugs 0.000 abstract description 67
- 229930101283 tetracycline Natural products 0.000 abstract description 67
- 150000003522 tetracyclines Chemical class 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 abstract description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 9
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 9
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 8
- 125000001769 aryl amino group Chemical group 0.000 description 8
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 8
- 125000004986 diarylamino group Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 229940040944 tetracyclines Drugs 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- IQIPCMYBFDOLBO-IRDJJEOVSA-N (4s,4as,5ar,12ar)-9-amino-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1C2=C(N(C)C)C=C(N)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O IQIPCMYBFDOLBO-IRDJJEOVSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010037151 Psittacosis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000005700 Stille cross coupling reaction Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Chemical group C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000000901 ornithosis Diseases 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003151 propanoic acid esters Chemical class 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- MTCQOMXDZUULRV-ADOAZJKMSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O MTCQOMXDZUULRV-ADOAZJKMSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- LGPKFIGMLPDYEA-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(N=C=O)C=C1 LGPKFIGMLPDYEA-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- SDCPFJIHUUMVDR-UHFFFAOYSA-N 4-boronooxybenzoic acid Chemical compound OB(O)OC1=CC=C(C(O)=O)C=C1 SDCPFJIHUUMVDR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- DHMYULZVFHHEHE-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(sulfanylidenemethylidene)carbamate Chemical compound C1=CC=C2C(COC(=O)N=C=S)C3=CC=CC=C3C2=C1 DHMYULZVFHHEHE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000194029 Enterococcus hirae Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012374 esterification agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229950000614 sancycline Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Ovaj izum se odnosi, barem djelomično, na nove 9- supstituirane minociklinske spojeve. Ovi minociklinski spojevi se mogu koristiti za liječenje brojnih stanja prijemljivih za tetraciklinske spojeve, kao što su bakterijske infekcije i neoplazme, kao i za druge poznate primjene za minociklinske i tetraciklinske spojeve općenito, kao što je blokiranje istjecanja tetraciklina i moduliranje ekspresije gena.The present invention relates, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat a number of conditions susceptible to tetracycline compounds, such as bacterial infections and neoplasms, as well as to other known uses for minocycline and tetracycline compounds in general, such as blocking tetracycline leakage and modulating gene expression.
Description
Srodne prijave Related applications
Ova prijava traži prioritet pred U.S. Privremenoj Prijavi Patenta Br. 60/275,621, naslovljenoj «9-Supstituirani Minociklinski Spojevi», podnešenoj 13. ožujka 2001, i U.S. Privremenoj Prijavi Patenta Br. 60/216,580, naslovljenoj «9-Substituirani Minociklinski spojevi», podnešenoj 7. srpnja 2000; obje ove prijave su ovdje uključene referencom. Ova prijava je srodna U.S. Privremenoj Prijavi Br. 60/154,701, podnešenoj 14. rujna 1999; Br. 60/193/972, podnešenoj 31. ožujka 2000; Br. 60/193,879, podnešenoj 31. ožujka 2000; br. 60/204,158, podnešenoj 15. svibnja 2000; Br. 60/212,030, podnešenoj 16. lipnja 2000; i Br. 60/212,471, podnešenoj 16 lipnja 2000, čiji su čitavi sadržaji ovdje u potpunosti uključeni referencom. This application claims priority to the U.S. Provisional Patent Application No. 60/275,621, entitled “9-Substituted Minocycline Compounds,” filed Mar. 13, 2001, and U.S. Pat. Provisional Patent Application No. 60/216,580, entitled "9-Substituted Minocycline Compounds", filed July 7, 2000; both of these applications are incorporated herein by reference. This application is related to U.S. Temporary Report No. 60/154,701, filed September 14, 1999; No. 60/193/972, filed on March 31, 2000; No. 60/193,879, filed March 31, 2000; no. 60/204,158, filed May 15, 2000; No. 60/212,030, filed June 16, 2000; and No. 60/212,471, filed Jun. 16, 2000, the entire contents of which are hereby incorporated by reference in their entirety.
Pozadina izuma Background of the invention
Razvoj tetraciklinskih antibiotika bio je direktan rezultat sustavnog ispitivanja uzoraka tla sakupljenih iz mnogih dijelova svijeta radi dokazivanja mikroorganizama sposobnih producirati bakteriocidne i/ili bakteriostatske smjese. Prvi od ovih novih spojeva je predstavljen 1948. pod nazivom klorotetraciklin. Dvije godine kasnije oksitetraciklin postaje dostupan. Detaljno objašnjenje kemijske strukture ovih sredstava potvrđuje njihovu sličnost i pruža analitičku osnovu proizvodnje trećeg člana ove skupine 1952, tetraciklina. Nova obitelj tetraciklinskih spojeva, bez prstenasto vezane metilne skupine prisutne u ranijim tetraciklinima, priređena je 1957. i postala dostupna javnosti 1967.; a minociklin je bio u upotrebi do 1972. The development of tetracycline antibiotics was a direct result of the systematic examination of soil samples collected from many parts of the world for the purpose of proving microorganisms capable of producing bacteriocidal and/or bacteriostatic compounds. The first of these new compounds was introduced in 1948 under the name chlorotetracycline. Two years later, oxytetracycline became available. A detailed explanation of the chemical structure of these agents confirms their similarity and provides an analytical basis for the production of the third member of this group in 1952, tetracycline. A new family of tetracycline compounds, without the ring-bound methyl group present in the earlier tetracyclines, was prepared in 1957 and became available to the public in 1967; and minocycline was in use until 1972.
U zadnje vrijeme, nastojanja istraživanja su fokusirana na razvijanje novih tetraciklinskih antibiotičkih smjesa djelotvornih pod različitim terapeutskim uvjetima i redoslijedima primjene. Također se istražuju novi tetraciklinski analozi koji bi se mogli dokazati kao jednako ili više djelotvorni od izvorno predstavljenih tetraciklinskih spojeva. Primjeri uključuju U.S. Patente Br. 2,980,584; 2,990,331; 3,062,717; 3,165,531; 3,454,697; 3,557,280; 3,674,859; 3,957,980; 4,018,889; 4,024,272; i 4,126,680. Ovi patenti su predstavnici raspona farmaceutski aktivnih tetraciklina i smjesa tetraciklinskih analoga. Recently, research efforts have been focused on the development of new tetracycline antibiotic mixtures effective under different therapeutic conditions and orders of application. New tetracycline analogs that may prove to be equally or more effective than the originally introduced tetracycline compounds are also being investigated. Examples include the U.S. Patent No. 2,980,584; 2,990,331; 3,062,717; 3,165,531; 3,454,697; 3,557,280; 3,674,859; 3,957,980; 4,018,889; 4,024,272; and 4,126,680. These patents are representatives of the range of pharmaceutically active tetracyclines and mixtures of tetracycline analogues.
Povijesno gledajući, ubrzo nakon njihovog početnog razvoja i predstavljanja, tetraciklini su se pokazali kao farmakološki visoko djelotvornima protiv riketsije; brojnih gram-pozitivnih i gram-negativnih bakterija; i faktora odgovornih za venerični limfogranulom, inkluzijski konjunktivitis, i psitakozu. Stoga su tetraciklini postali poznati kao antibiotici “širokog spektra”. Sa slijedećom potvrdom njihove in vitro antimikropske aktivnosti, djelotvornosti u pokusnim infekcijama, i farmakoloških svojstava, tetraciklini kao skupina brzo postaju u širokoj upotrebi u terapeutske svrhe. Međutim široko rasprostranjena upotreba tetraciklina za ozbiljne i manje ozbiljne bolesti i oboljenja dovelo je direktno do pojave otpornosti na te antibiotike čak i kod visoko prijemljivih vrsta bakterija, i to kod komenzalnih i patogenih (npr. pneumococcus i Salmonella). Porast tetraciklin otpornih organizama je rezultirao sveopćim padom upotrebe tetraciklina i smjesa tetraciklinskih analoga kao izabranih antibiotika. Historically, shortly after their initial development and introduction, tetracyclines have been shown to be pharmacologically highly effective against rickettsiae; numerous gram-positive and gram-negative bacteria; and factors responsible for lymphogranuloma venereum, inclusion conjunctivitis, and psittacosis. Therefore, tetracyclines became known as "broad-spectrum" antibiotics. With the subsequent confirmation of their in vitro antimicrobial activity, efficacy in experimental infections, and pharmacological properties, tetracyclines as a group are rapidly becoming widely used for therapeutic purposes. However, the widespread use of tetracycline for serious and less serious diseases and ailments has led directly to the emergence of resistance to these antibiotics even in highly susceptible types of bacteria, both commensal and pathogenic (eg pneumococcus and Salmonella). The increase in tetracycline-resistant organisms has resulted in a general decline in the use of tetracyclines and mixtures of tetracycline analogs as antibiotics of choice.
Sažetak izuma Summary of the invention
Ovaj izum se odnosi, barem djelomično, na minociklinske spojeve iz formule I: This invention relates, at least in part, to minocycline compounds of formula I:
[image] (I) [image] (I)
gdje su: where are they:
X je CHC(R13Y'Y), CR6'R6, S, NR6, ili O; X is CHC(R13Y'Y), CR6'R6, S, NR6, or O;
R2, R4', R4'', R7' i R7'' su svaki hidrogen, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, aril, heterociklička, heteroaromatska ili pred-lijek jedinica; R2, R4', R4'', R7'' and R7'' are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or prodrug unit;
R4 je NR4'R4'', alkil, alkenil, alkinil, aril, hidroksil, halogen, ili hidrogen; R4 is NR4'R4'', alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;
R2', R3, R10, R11 i R12 su svaki hidrogen ili pred-lijek jedinice; R2', R3, R10, R11 and R12 are each hydrogen or a prodrug unit;
R5 je hidroksil, hidrogen, tiol, alkanoil, aroil, alkaroil, aril, heteroaromatik, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, alkil karboniloksi, ili aril karboniloksi; R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkylcarbonyloxy, or arylcarbonyloxy;
R6 i R6' su neovisno hidrogen, metilen, absent, hidroksil, halogen, tiol, alkil, alkenil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R6 and R6' are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
R9 je nitro, alkil, alkenil, alkinil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, arilalkil, amino, arilalkenil, arilalkinil, tionitrozo, R9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, thionitroso,
ili –(CH2)0-3NR9cC(=Z')ZR9a; or –(CH2)0-3NR9cC(=Z')ZR9a;
Z je CR9dR9e, S, NR9b ili O; Z is CR9dR9e, S, NR9b or O;
Z' je NR9f, O ili S; Z' is NR9f, O or S;
NR9a, NR9b, NR9c, NR9d, NR9e i NR9f su svaki neovisno hidrogen, acil, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, aril, heterociklička, heteroaromatska ili pred-lijek jedinica; NR9a, NR9b, NR9c, NR9d, NR9e and NR9f are each independently a hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or prodrug unit;
R8 je hidrogen, hidroksil, halogen, tiol, alkil, alkenil, alkinil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R 8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
R13 je hidrogen, hidroksi, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
Y' i Y su svaki neovisno hidrogen, halogen, hidroksil, cijano, sulfidril, amino, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil, i farmaceutski prihvatljive soli, esteri i pred-lijekovi istih. Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl, and pharmaceutically acceptable salts, esters, and prodrugs thereof.
Izum se također odnosi, barem djelomično, na 9-supstituirane minociklinske spojeve sa formulom (II): The invention also relates, at least in part, to 9-substituted minocycline compounds of formula (II):
[image] (II) [image] (II)
gdje su: where are they:
R4', R4'', R7' i R7'' su svaki alkil; i R4', R4'', R7'' and R7'' are each alkyl; and
R9 je piridiletinil skupina; alkenilkarbamat skupina; halogena skupina; alkilakrilat skupina; naptil skupina; haloacetil skupina; alkil karbamat skupina; ciklopentil ili ciklopentenil skupina; benzofuranil skupina; fenilpropiononamino skupina; tosilamino skupina; metoksipiridil skupina; alkenamino skupina; N-t-butil skupina; t-butilamid skupina; hidroksibutilamino skupina; hidroksipropilamino skupina; fenil skupina; nitrofenil skupina; aminofenil skupina; alkoksifenil skupina; halofenil urea skupina; cijanofenil skupina; karboksifenil skupina; acilfenil skupina; alkilfenil skupina; halofenil skupina; alkoksifenil skupina; karboksialkilfenil skupina; fenilalkinil skupina; alkinil skupina; alkilglicinetilester skupina; stiren skupina; tiofen skupina; i alkilaminofosfo skupina; i farmaceutski prihvatljive soli, esteri i pred-lijekovi istih. R 9 is a pyridylethynyl group; alkenylcarbamate group; halogen group; an alkylacrylate group; napthyl group; haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; benzofuranyl group; phenylpropiononamino group; tosylamino group; methoxypyridyl group; an alkenamino group; N-t-butyl group; t-butylamide group; hydroxybutylamino group; hydroxypropylamino group; phenyl group; nitrophenyl group; aminophenyl group; Alkoxyphenyl group; halophenyl urea group; cyanophenyl group; carboxyphenyl group; acylphenyl group; an alkylphenyl group; halophenyl group; Alkoxyphenyl group; a carboxyalkylphenyl group; phenylalkynyl group; alkynyl group; alkyl glycine ethyl ester group; styrene group; thiophene group; and an alkylaminophospho group; and pharmaceutically acceptable salts, esters and prodrugs thereof.
Izum se također odnosi na metode upotrebe minociklinskih spojeva iz izuma za tretman subjekata koji pate od stanja koja se mogu tretirati upotrebom minociklinskih spojeva iz izuma. The invention also relates to methods of using the minocycline compounds of the invention for the treatment of subjects suffering from conditions that can be treated using the minocycline compounds of the invention.
Izum se također odnosi na farmaceutske smjese koje sadrže minociklinske spojeve iz izuma i farmaceutski prikladne nosače. Izum se također odnosi na upotrebu minociklinskog spoja iz izuma za proizvodnju ljekova, npr. ljekova za tretman stanja prijemljivih za tetraciklin. The invention also relates to pharmaceutical compositions containing the minocycline compounds of the invention and pharmaceutically suitable carriers. The invention also relates to the use of the minocycline compound of the invention for the manufacture of medicaments, eg medicaments for the treatment of conditions susceptible to tetracycline.
Detaljan opis izuma Detailed description of the invention
Ovaj izum se odnosi, barem djelomično, na nove 9-supstituirane minociklinske spojeve. Ovi minociklinski spojevi se mogu koristiti za tretiranje brojnih stanja prijemljivih za tetraciklinkse spojeve, kao što su bakterijske infekcije i neoplazme, isto kao i druge poznate primjene za minociklinske i tetraciklinske spojeve općenito, kao što je blokiranje istjecanja tetraciklina i moduliranje ekpresije gena. This invention relates, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat a number of tetracycline-susceptible conditions, such as bacterial infections and neoplasms, as well as other known uses for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulating gene expression.
Izum se također odnosi , barem djelomično, na minociklinske spojeve iz formule I: The invention also relates, at least in part, to minocycline compounds of formula I:
[image] (I) [image] (I)
gdje su: where are they:
X je CHC(R13Y'Y), CR6'R6, S, NR6, ili O; X is CHC(R13Y'Y), CR6'R6, S, NR6, or O;
R2, R4', R4'', R7' i R7'' su svaki hidrogen, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, aril, heterociklička, heteroaromatska ili pred-lijek jedinica; R2, R4', R4'', R7'' and R7'' are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or prodrug unit;
R4 je NR4'R4'', alkil, alkenil, alkinil, aril, hidroksil, halogen, ili hidrogen; R4 is NR4'R4'', alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen;
R2', R3, R10, R11 i R12 su svaki hidrogen ili pred-lijek jedinica; R2', R3, R10, R11 and R12 are each hydrogen or a prodrug unit;
R5 je hidroksil, hidrogen, tiol, alkanoil, aroil, alkaroil, aril, heteroaromatik, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, alkil karboniloksi, ili aril karboniloksi; R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkylcarbonyloxy, or arylcarbonyloxy;
R6 i R6' su neovisno hidrogen, metilen, absent, hidroksil, halogen, tiol, alkil, alkenil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R6 and R6' are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
R9 je nitro, alkil, alkenil, alkinil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, arilalkil, amino, arilalkenil, arilalkinil, tionitrozo, R9 is nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, thionitroso,
ili –(CH2)0-3NR9cC(=Z')ZR9a; or –(CH2)0-3NR9cC(=Z')ZR9a;
Z je CR9dR9e, S, NR9b ili O; Z is CR9dR9e, S, NR9b or O;
Z' je NR9f, O ili S; Z' is NR9f, O or S;
NR9a, NR9b, NR9c, NR9d, NR9e i NR9f su svaki neovisno hidrogen, acil, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, arilalkil, aril, heterociklička, heteroaromatska ili pred-lijek jedinica; NR9a, NR9b, NR9c, NR9d, NR9e and NR9f are each independently a hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or prodrug unit;
R8 je hidrogen, hidroksil, halogen, tiol, alkil, alkenil, alkinil, aril, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R 8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
R13 je hidrogen, hidroksi, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil; R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl;
Y' i Y su svaki neovisno hidrogen, halogen, hidroksil, cijano, sulfidril, amino, alkil, alkenil, alkinil, alkoksi, alkiltio, alkilsulfinil, alkilsulfonil, alkilamino, ili arilalkil, i farmaceutski prihvatljive soli, esteri i pred-lijekovi istih. Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or arylalkyl, and pharmaceutically acceptable salts, esters, and prodrugs thereof.
Izraz minociklinski spojevi odnosi se na spojeve iz gore navedene formule (I). U jednom sastavnom dijelu, izraz minociklinski spojevi uključuje spojeve gdje su: X je CR6R6'; R2', R2', R5, R6, R6', R8, R9, R10, R11 i R12 su svaki hidrogen; R4 je NR4'R4'';R4', R4'', R7' i R7'' su svaki niži alkil, npr. metil. The term minocycline compounds refers to the compounds of the above-mentioned formula (I). In one embodiment, the term minocycline compounds includes compounds wherein: X is CR6R6'; R2', R2', R5, R6, R6', R8, R9, R10, R11 and R12 are each hydrogen; R4 is NR4'R4''; R4', R4'', R7'' and R7'' are each lower alkyl, eg methyl.
Primjeri R9 uključuju supstituirane i nesupstituirane aril skupine. Aril skupine uključuju supstituirane i nesupstituirane heteroarile (npr. furanil, imidazolil, benzotiofenil, benzofuranil, kvinolinil, izokvinolinil, benzodioksazolil, benzoksazolil, benzotiazolil, benzoimidazolil, metilendioksifenil, indolil, tienil, pirimidil, pirazinil, purinil, pirazolil, oksazolil, izooksazolil, naftridinil, tiazolil, izotiazolil, ili deazapurinil), supstituirani i nesupstituirani fenil, i skupine sa više od jednog aromatskog prstena, kao što je naftil. Examples of R9 include substituted and unsubstituted aryl groups. Aryl groups include substituted and unsubstituted heteroaryls (eg, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isoxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl), substituted and unsubstituted phenyl, and groups with more than one aromatic ring, such as naphthyl.
Primjeri supstituenata od R9 uključuju, ali nisu ograničeni na, alkil, alkenil, halogen, hidroksil, alkoksi, alkilkarboniloksi, alkiloksikarbonil, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminokarbonil, arilalkil, aminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, silil, aminokarbonil, alkiltiokarbonil, fosfat, aralkil, fosfonato, fosfinato, cijano, amino, acilamino, amido, imino, sulfidril, alkiltio, sulfat, ariltio, tiokarboksilat, alkilsulfinil, sulfonat, sulfamoil, sulfonamido, nitro, cijano, azido, heterociklil, alkilaril, aril i heteroaril. Examples of substituents on R9 include, but are not limited to, alkyl, alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, arylalkyl, aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl. . , heterocyclyl, alkylaryl, aryl and heteroaryl.
U daljnjem sastavnom dijelu, aril R9 skupina je supstituirana sa jednim ili više supstituenata kao što su, na primjer karboksilat, alkil, alkenil, alkinil, aril, heterociklici, cijano, amino, halogen, alkoksi, alkoksikarbonil, amido, alkilkarbonil, ili nitro. In a further component, the aryl R9 group is substituted with one or more substituents such as, for example, carboxylate, alkyl, alkenyl, alkynyl, aryl, heterocyclic, cyano, amino, halogen, alkoxy, alkoxycarbonyl, amido, alkylcarbonyl, or nitro.
U drugom sastavnom dijelu R9 je supstituirani ili nesupstituirani alkinil. Alkinil R9 skupina može biti supstituirana sa supstituiranom ili nesupstituiranom aril skupinom, kao što je na primjer fenil. Mogući supstituenti za supstituiranu fenil skupinu uključuju, na primjer, one navedene iznad, za aril R9 skupinu. Nadalje, supstituirana R9 skupina može biti supstituirana sa heteroaril (npr. piridinil), alkil (npr. metil, etil, propil, butil, pentil, heksil, ciklopropil, ciklobutil, ciklopentil, cikloheksil, itd.), alkenil (npr. etenil, propenil, butenil, pentenil, heksenil, itd.), karboksilat, silil (npr. trialkilsilil, npr. trimetilsilil), aralkil, ili alkiloksikarbonil skupinom. In the second component, R9 is substituted or unsubstituted alkynyl. The alkynyl R 9 group may be substituted with a substituted or unsubstituted aryl group, such as for example phenyl. Possible substituents for the substituted phenyl group include, for example, those listed above for the aryl R9 group. Furthermore, the substituted R 9 group may be substituted with heteroaryl (e.g., pyridinyl), alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.), alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, etc.), carboxylate, silyl (eg trialkylsilyl, eg trimethylsilyl), aralkyl, or alkyloxycarbonyl group.
Svaka od ovih skupina može također biti nadalje supstiruirana, sa takvim supstituentima kao što su alkil, alkenil, halogen, hidroksil, alkoksi, alkilkarboniloksi, alkiloksikarbonil, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminokarbonil, arilalkil, aminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, silil, aminokarbonil, alkiltiokarbonil, fosfat, aralkil, fosfonato, fosfinato, cijano, amino, acilamino, amido, imino, sulfidril, alkiltio, sulfat, ariltio, tiokarboksilat, alkilsulfinil, sulfonat, sulfamoil, sulfonamido, nitro, cijano, azido, heterociklil, alkilaril, aril i heteroaril. Each of these groups may also be further substituted, with such substituents as alkyl, alkenyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, arylalkyl, aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfidryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
U daljnjem sastavnom dijelu, alkinil R9 skupina je supstituirana sa aminoalkil skupinom. Aminoalkil skupina se tada također može supstiruirati sa, na primjer, alkil, alkenil, alkinil, acil, karbonil, ili alkilsulfon skupinom. In a further component, the alkynyl R9 group is substituted with an aminoalkyl group. The aminoalkyl group can then also be substituted with, for example, an alkyl, alkenyl, alkynyl, acyl, carbonyl, or alkylsulfone group.
U drugom daljnjem sastavnom dijelu, alkinil R9 skupina je supstituirana sa cikloalkenil skupinom, kao što je, na primjer ciklopenten. In another further component, the alkynyl R 9 group is substituted with a cycloalkenyl group, such as, for example, cyclopentene.
U drugom sastavnom dijelu, R9 je alkil. Alkil skupina može biti supstituirana ili nesupstituirana. Primjeri alkil skupina uključuju, na primjer ravnolančane, razgranate i cikličke alkil skupine. Na primjer alkil skupine uključuju metil, etil, i-propil, n-propil, i-butil, n-butil, t-butil, pentil, heksil, heptil, oktil, nonil, decil, itd. Cikličke alkil skupine uključuju skupine sa jednim ili više prstenova, kao što su na primjer ciklopropan, ciklobutan, ciklopentan, cikloheksan, cikloheptan, itd. U jednom sastavnom dijelu, alkil R9 skupina je 2-ciklopentiletil. In another component, R 9 is alkyl. The alkyl group can be substituted or unsubstituted. Examples of alkyl groups include, for example, straight chain, branched and cyclic alkyl groups. For example, alkyl groups include methyl, ethyl, i-propyl, n-propyl, i-butyl, n-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. Cyclic alkyl groups include groups with one or multiple rings, such as, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, etc. In one embodiment, the alkyl R 9 group is 2-cyclopentylethyl.
Primjeri supstituenata za alkil skupine uključuju, na primjer halogene (npr. fluorin, klorin, bromin, jodin, itd.), hidroksil, alkoksi (npr., metoksi, etoksi, propoksi, butoksi, pentoksi, perfluorometoksi, perklorometoksi, itd.), alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminoakarbonil, arilalkil aminokarbonil, alkenilaminokarbonil, karboksi, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, silil, aminokarbonil, alkiltiokarbonil, fosfat, fosfonato, fosfinato, cijano, amino, acilamino, amido, imino, sulfidril, alkiltio, ariltio, tiokarboksilat, sulfat, alkilsulfinil, alkenil, sulfonat, sulfamoil, sulfonamido, nitro, alkenil, cijano, azido, heterociklil, alkilaril, aril i heteroaril. Examples of substituents for alkyl groups include, for example, halogens (eg, fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy (eg, methoxy, ethoxy, propoxy, butoxy, pentoxy, perfluoromethoxy, perchloromethoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, carboxy, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido , imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, alkenyl, sulfonate, sulfamoyl, sulfonamido, nitro, alkenyl, cyano, azido, heterocyclyl, alkylaryl, aryl, and heteroaryl.
U drugom sastavnom dijelu, minociklinski spoj iz izuma je spoj gdje: R9 je –NR9cC(=Z’)ZR9a, –CH2NR9cC(=Z’)ZR9a, –(CH2)2NR9cC(=Z’)ZR9a, ili –(CH2)3 NR9cC(=Z’)ZR9a. U određenim sastavnim dijelovima, R9 je –NR9cC(=Z’)ZR9a ili –CH2NR9cC(=Z’)ZR9a. Primjeri R9c uključuju vodik. Z’ može biti, na primjer S, NH, ili O. Primjeri Z uključuju NR9b (npr. kada je R9b vodik, alkil, itd.), O ili S. In another component, the minocycline compound of the invention is a compound where: R9 is –NR9cC(=Z')ZR9a, –CH2NR9cC(=Z')ZR9a, –(CH2)2NR9cC(=Z')ZR9a, or –(CH2) 3 NR9cC(=Z')ZR9a. In certain embodiments, R9 is -NR9cC(=Z')ZR9a or -CH2NR9cC(=Z')ZR9a. Examples of R9c include hydrogen. Z' can be, for example, S, NH, or O. Examples of Z include NR9b (eg, when R9b is hydrogen, alkyl, etc.), O, or S.
Primjeri R9a skupina uključuju aril skupine kao što je supstituirani i nesupsituirani fenil. Primjeri mogućih supstituenata za aril R9a skupine uključuju, ali nisu ograničeni na, alkil (npr. metil, etil, propil, butil, pentil, heksil, perfluormetil, perkloroetil, itd.), alkenil, halogen (npr. fluorin, klorin, bromin, jodin, itd.), hidroksil, alkoksi (npr. metoksi, etoksi, propoksi, perfluorometoksi, perklorometoksi, itd.), alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminoakarbonil, arilalkil aminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, silil, aminokarbonil, alkiltiokarbonil, fosfat, fosfonato, fosfinato, cijano, amino, acilamino, amido, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfat, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, acetil, alkil, cijano, azido, heterociklil, alkilaril, aril i heteroaril skupine. Examples of R9a groups include aryl groups such as substituted and unsubstituted phenyl. Examples of possible substituents for aryl R9a groups include, but are not limited to, alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, perfluoromethyl, perchloroethyl, etc.), alkenyl, halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxyl, alkoxy (eg, methoxy, ethoxy, propoxy, perfluoromethoxy, perchloromethoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl , alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, acetyl, alkyl , cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl groups.
U određenim sastavnim dijelovima, barem jedan od supstituenata supstituiranog fenila je nitro, alkoksi (npr. metoksi, metlenedioksi, perfluorometoksi) alkil (npr. metil, etil, propil, butil, ili pentil), acetil, halogen (npr. fluorin, klorin, bromin, ili jodin), ili amino (npr. dialkilamino). U određenim sastavnim dijelovima, alkoksi skupina je perhalogenirana, npr. perfluorometoksi. In certain embodiments, at least one of the substituted phenyl substituents is nitro, alkoxy (e.g., methoxy, methylenedioxy, perfluoromethoxy), alkyl (e.g., methyl, ethyl, propyl, butyl, or pentyl), acetyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), or amino (eg dialkylamino). In certain components, the alkoxy group is perhalogenated, eg perfluoromethoxy.
Primjeri aril R9a skupina uključuju, ali nisu ograničeni na, nesupstituirani fenil, para-nitrofenil, para-metoksi fenil, para-perfluorometoksi fenil, para-acetil fenil, 3, 5-metilendioksifenil, 3,5-diperfluorometil fenil, para-bromo fenil, para-kloro fenil, i para-fluoro fenil. Examples of aryl R9a groups include, but are not limited to, unsubstituted phenyl, para-nitrophenyl, para-methoxy phenyl, para-perfluoromethoxy phenyl, para-acetyl phenyl, 3,5-methylenedioxyphenyl, 3,5-diperfluoromethyl phenyl, para-bromo phenyl , para-chloro phenyl, and para-fluoro phenyl.
Drugi primjeri aril R9a skupina uključuju supstituirane i nesupstituirane heterocikličke spojeve (npr. furanil, imidazolil, benzotiofenil, benzofuranil, kvinolinil, izokvinolinil, benzodioksazolil, benzoksazolil, benzotiazolil, benzoimidazolil, metilendioksifenil, indolil, tienil, pirimidil, pirazinil, purinil, pirazolil, pirolidinil, oksazolil, izooksazolil, naftridinil, tiazolil, izotiazolil, ili deazapurinil) i supstituirane i nesupstituirane biaril skupine, kao što je naftil i fluoren. Other examples of aryl R9a groups include substituted and unsubstituted heterocyclic compounds (eg, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, pyrrolidinyl, oxazolyl, isoxazolyl, naphthridinyl, thiazolyl, isothiazolyl, or deazapurinyl) and substituted and unsubstituted biaryl groups, such as naphthyl and fluorene.
R9a također može biti supstituirani ili nesupstituirani alkil, npt, metil, etil, propil, butil, pentil, itd. Primjeri supstituenata uključuju ali nisu ograničeni na halogene (npr. fluorin, bromin, klorin, jodin, itd.), hidroksil, alkoksi (npr. metoksi, etoksi, propoksi, butoksi, itd.), alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminoakarbonil, arilalkil aminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, silil, aminokarbonil, alkiltiokarbonil, fosfat, fosfonato, fosfinato, cijano, amino, acilamino, amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfat, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, alkenil, heterociklil, alkilaril, aril i heteroaril. R 9a can also be substituted or unsubstituted alkyl, npt, methyl, ethyl, propyl, butyl, pentyl, etc. Examples of substituents include but are not limited to halogen (eg, fluorine, bromine, chlorine, iodine, etc.), hydroxyl, alkoxy ( e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate , phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, alkenyl, heterocyclyl, alkylaryl, aryl, and heteroaryl. .
R9a također može biti supstituirani ili nesupstituirani alkenil. Primjeri supstituenata za alkenil R9a skupine uključuju one gore navedene za alkil R9a skupine. Primjeri alkenil R9a skupina uključuju pent-1-enil. R 9a can also be substituted or unsubstituted alkenyl. Examples of substituents for alkenyl R9a groups include those listed above for alkyl R9a groups. Examples of alkenyl R9a groups include pent-1-enyl.
U jednom sastavnom dijelu, Z’ je NH, Z je NH, a R9a je alkil. In one embodiment, Z' is NH, Z is NH, and R 9a is alkyl.
Izum se također odnosi na spojeve gdje je R9 aminoalkil (npr. aminometil). Aminoalkil R9 skupine mogu biti dalje supstituirane. Primjeri supstituenata uključuju aril skupine, kao što su, na primjer supstituirani ili nesupstituirani fenil (npr. metilendioksifenil ili para-perfluorometoksifenil), ili heteraromatske skupine koje omogućuju spoju iz izuma da izvodi njegovu namjenjenu funkciju. The invention also relates to compounds where R 9 is aminoalkyl (eg aminomethyl). Aminoalkyl R9 groups can be further substituted. Examples of substituents include aryl groups, such as, for example, substituted or unsubstituted phenyl (eg methylenedioxyphenyl or para-perfluoromethoxyphenyl), or heteroaromatic groups which enable the compound of the invention to perform its intended function.
Primjeri minociklinskih spojeva iz izuma uključuju one navedene u Tabeli 1, kao i one navedene ispod: Examples of minocycline compounds of the invention include those listed in Table 1, as well as those listed below:
[image] [image]
Farmaceutski prihvatljive soli ovih spojeva su također uključene. Drugi spojevi iz ovog izuma su navedeni u tabeli 1. Pharmaceutically acceptable salts of these compounds are also included. Other compounds of this invention are listed in Table 1.
Izum se također odnosi, barem djelomično, na 9-supstituirani minociklinski spoj slijedeće formule: The invention also relates, at least in part, to a 9-substituted minocycline compound of the following formula:
[image] (II) [image] (II)
gdje su: where are they:
R4’, R4”, R7’, i R7” su svaki alkil; i R4', R4", R7', and R7" are each alkyl; and
R9 je piridiletinil skupina; alkenilkarbamat skupina; halogen skupina; alkilakrilat skupina; naftil urea skupina; haloacetil skupina; alkil karbamat skupina; ciklopentil ili ciklopentenil skupina; benzofuranil skupina; fenilpropiononamino skupina; tosilamino skupina; metoksipiridil skupina; alkenamino skupina; N-t-butil skupina; t-butilamid skupina; hidroksibutilamino skupina; hidroksipropilamino skupina; fenil skupina; nitrofenil skupina; nitrofenil alkinil skupina; aminofenil skupina; halofenil urea skupina; alkoksifenil skupina; cijanofenil skupina; karboksifenil skupina; acilfenil skupina; alkilfenil skupina; halofenil skupina; alkoksifenil skupina; karboksialkilfenil skupina; fenilalkinil skupina; alkinil skupina; alkilglicinetilester skupina; stiren skupina; tiofen skupina; alkilaminofosfo skupina; i farmaceutski prihvatljive soli istih. R 9 is a pyridylethynyl group; alkenylcarbamate group; halogen group; an alkylacrylate group; naphthyl urea group; haloacetyl group; an alkyl carbamate group; a cyclopentyl or cyclopentenyl group; benzofuranyl group; phenylpropiononamino group; tosylamino group; methoxypyridyl group; an alkenamino group; N-t-butyl group; t-butylamide group; hydroxybutylamino group; hydroxypropylamino group; phenyl group; nitrophenyl group; nitrophenyl alkynyl group; aminophenyl group; halophenyl urea group; Alkoxyphenyl group; cyanophenyl group; carboxyphenyl group; acylphenyl group; an alkylphenyl group; halophenyl group; Alkoxyphenyl group; a carboxyalkylphenyl group; phenylalkynyl group; alkynyl group; alkyl glycine ethyl ester group; styrene group; thiophene group; an alkylaminophospho group; and pharmaceutically acceptable salts thereof.
Izraz "9-supstituirani minociklinski spoj” uključuje minociklinske spojeve sa supstituentom na poziciji 9. U drugom sastavnom dijelu, spoj je derivat minociklina. The term "9-substituted minocycline compound" includes minocycline compounds with a substituent at the 9-position. In another embodiment, the compound is a derivative of minocycline.
U jednom sastavnom dijelu, R9 je alkenilkarbamat skupina. Primjeri tetraciklinksih spojeva sa ovim R9 supstituentom uključuju 9-izopropenil karbamat minociklin. In one embodiment, R 9 is an alkenylcarbamate group. Examples of tetracycline compounds with this R 9 substituent include the 9-isopropenyl carbamate minocycline.
U jednom sastavnom dijelu, R9 je piridiletinil skupina. Primjeri tetraciklinksih spojeva sa ovim R9 supstituentom uključuju 9-(2-piridiletinil) minociklin. In one embodiment, R 9 is a pyridylethynyl group. Examples of tetracycline compounds with this R 9 substituent include 9-(2-pyridylethynyl) minocycline.
U jednom sastavnom dijelu, R9 je halogena skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-jodo minociklin. In one embodiment, R 9 is a halogen group. Exemplary tetracycline compounds with this R9 substituent include 9-iodo minocycline.
U jednom sastavnom dijelu, R9 je alkilakrilat skupina. Primjeri tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-butilakrilat minociklin. In one embodiment, R 9 is an alkylacrylate group. Examples of tetracycline compounds with this R 9 substituent include 9-butyl acrylate minocycline.
U jednom sastavnom dijelu, R9 je naftil urea skupina. Primjeri tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-naftil minociklin urea. In one embodiment, R 9 is a naphthyl urea group. Examples of tetracycline compounds with this R9 substituent include 9-naphthyl minocycline urea.
U jednom sastavnom dijelu, R9 je haloacetil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-kloroacetil minociklin urea. In one embodiment, R 9 is a haloacetyl group. Exemplary tetracycline compounds with this R9 substituent include 9-chloroacetyl minocycline urea.
U jednom sastavnom dijelu, R9 je alkil karbamat skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-neopentil minociklin karbamat. In one embodiment, R 9 is an alkyl carbamate group. Exemplary tetracycline compounds with this R 9 substituent include 9-neopentyl minocycline carbamate.
U jednom sastavnom dijelu, R9 je ciklopentil ili ciklopentenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-ciklopenten minociklin. In one embodiment, R 9 is a cyclopentyl or cyclopentenyl group. Exemplary tetracycline compounds with this R9 substituent include 9-cyclopentene minocycline.
U jednom sastavnom dijelu, R9 je benzofuranil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-benzofuranil minociklin. In one embodiment, R 9 is a benzofuranyl group. Exemplary tetracycline compounds with this R9 substituent include 9-benzofuranyl minocycline.
U jednom sastavnom dijelu, R9 je fenilpropiononamino skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(fenilpropiononamino) minociklin. In one embodiment, R9 is a phenylpropiononamino group. Exemplary tetracycline compounds with this R 9 substituent include 9-(phenylpropiononamino) minocycline.
U jednom sastavnom dijelu, R9 je tozilamino skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-tozilamino minociklin. In one embodiment, R 9 is a tosylamino group. Exemplary tetracycline compounds with this R9 substituent include 9-tosylamino minocycline.
U jednom sastavnom dijelu, R9 je metoksipiridil skupina. Primjer tetraciklinskih spojeva sa ovim R5 supstituentom uključuju 9-(2-metoksi-3-piridil) minociklin. In one embodiment, R 9 is a methoxypyridyl group. Exemplary tetracycline compounds with this R 5 substituent include 9-(2-methoxy-3-pyridyl) minocycline.
U jednom sastavnom dijelu, R5 je alkenamino skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(N-2'-hidroksidecil-9'-en-amino) minociklin. In one embodiment, R 5 is an alkenamino group. Exemplary tetracycline compounds with this R 9 substituent include 9-(N-2'-hydroxydecyl-9'-ene-amino) minocycline.
U jednom sastavnom dijelu, R9 je N-t-butil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju N-t-butil-minociklin HCl. In one embodiment, R 9 is an N-t-butyl group. Exemplary tetracycline compounds with this R9 substituent include N-t-butyl-minocycline HCl.
U jednom sastavnom dijelu, R9 je t-butilamid skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-BOC-NH minociklin. In one embodiment, R 9 is a t-butylamide group. Exemplary tetracycline compounds with this R9 substituent include 9-BOC-NH minocycline.
U jednom sastavnom dijelu, R9 je hidroksibutilamino skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(N-2'-hidroksibutilamino) minociklin. In one embodiment, R 9 is a hydroxybutylamino group. Exemplary tetracycline compounds with this R 9 substituent include 9-(N-2'-hydroxybutylamino) minocycline.
U jednom sastavnom dijelu, R9 je hidroksipropilamino skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(N-3-kloro, 2-hidroksilpropilamino) minociklin. In one embodiment, R 9 is a hydroxypropylamino group. Exemplary tetracycline compounds with this R 9 substituent include 9-(N-3-chloro, 2-hydroxylpropylamino) minocycline.
U jednom sastavnom dijelu, R9 je fenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-fenil minociklin HCl i 9-p-tolil minociklin. In one embodiment, R 9 is a phenyl group. Exemplary tetracycline compounds with this R9 substituent include 9-phenyl minocycline HCl and 9-p-tolyl minocycline.
U jednom sastavnom dijelu, R9 je nitrofenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(3'-nitrofenil) minociklin. In one embodiment, R 9 is a nitrophenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(3'-nitrophenyl) minocycline.
U jednom sastavnom dijelu, R9 je nitrofenil alkinil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4'-nitrofeniletinil) minociklin. In one embodiment, R 9 is a nitrophenyl alkynyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4'-nitrophenylethynyl) minocycline.
U jednom sastavnom dijelu, R9 je aminofenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(3-aminofenil) minociklin. In one embodiment, R 9 is an aminophenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(3-aminophenyl) minocycline.
U jednom sastavnom dijelu, R9 je halofenil urea skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4-kloro,2-trifluorometilfenil) minociklin urea. In one embodiment, R 9 is a halophenyl urea group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4-chloro,2-trifluoromethylphenyl) minocycline urea.
U jednom sastavnom dijelu, R9 je alkoksifenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(p-metoksifenil) minociklin, 9-(4'-metoksifenil) minociklin, i 9-(3,4-metilendioksifenil) minociklin. In one embodiment, R 9 is an alkoxyphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(p-methoxyphenyl) minocycline, 9-(4'-methoxyphenyl) minocycline, and 9-(3,4-methylenedioxyphenyl) minocycline.
U jednom sastavnom dijelu, R9 je cijanofenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4'-cijanofenil) minociklin. In one embodiment, R 9 is a cyanophenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4'-cyanophenyl) minocycline.
U jednom sastavnom dijelu, R9 je karboksialkilfenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4'-karboksifenil) minociklin. In one embodiment, R 9 is a carboxyalkylphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4'-carboxyphenyl) minocycline.
U jednom sastavnom dijelu, R9 je acilfenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(3-formilfenil) minociklin. In one embodiment, R 9 is an acylphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(3-formylphenyl) minocycline.
U jednom sastavnom dijelu, R9 je alkilfenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4'-t-butilfenil) minociklin. In one embodiment, R 9 is an alkylphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4'-t-butylphenyl) minocycline.
U jednom sastavnom dijelu, R9 je halofenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(3-klorofenil) minociklin, 9-(2',4'-difluorofenil) minociklin, 9-(3,4-difluorofenil) minociklin, 9-(4'-klorofenil) minociklin, 9-(3,4-diklorofenil) minociklin, i 9-(4'-trifluorometilfenil) minociklin. In one embodiment, R 9 is a halophenyl group. Exemplary tetracycline compounds with this R9 substituent include 9-(3-chlorophenyl) minocycline, 9-(2',4'-difluorophenyl) minocycline, 9-(3,4-difluorophenyl) minocycline, 9-(4'-chlorophenyl) minocycline , 9-(3,4-dichlorophenyl) minocycline, and 9-(4'-trifluoromethylphenyl) minocycline.
U jednom sastavnom dijelu, R9 je alkoksifenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(3-etoksifenil) minociklin. In one embodiment, R 9 is an alkoxyphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(3-ethoxyphenyl) minocycline.
U jednom sastavnom dijelu, R9 je karboksialkilfenil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(4-karboksimetilfenil) minociklin. In one embodiment, R 9 is a carboxyalkylphenyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(4-carboxymethylphenyl) minocycline.
U jednom sastavnom dijelu, R9 je fenilalkinil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(feniletinil) minociklin, 9-(3-hidroksifeniletinil) minociklin, 9-(p-toliletinil) minociklin, i 9-(p-metoksifeniletinil) minociklin. In one embodiment, R 9 is a phenylalkynyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-(phenylethynyl) minocycline, 9-(3-hydroxyphenylethynyl) minocycline, 9-(p-tolylethynyl) minocycline, and 9-(p-methoxyphenylethynyl) minocycline.
U jednom sastavnom dijelu, R9 je alkinil skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-etinil minociklin, 9-(p-fluoroetinil) minociklin, 9-(trimetilsililetinil) minociklin, 9-(propionil) minociklin, 9-(ciklohekseniletinil) minociklin, i 9-(1-cikloheksil-1-hidroksietinil) minociklin. In one embodiment, R 9 is an alkynyl group. Exemplary tetracycline compounds with this R 9 substituent include 9-ethynyl minocycline, 9-(p-fluoroethynyl) minocycline, 9-(trimethylsilylethynyl) minocycline, 9-(propionyl) minocycline, 9-(cyclohexylethynyl) minocycline, and 9-(1-cyclohexyl) minocycline. -1-hydroxyethynyl) minocycline.
U jednom sastavnom dijelu, R9 je alkilglicinetilester skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-propilglicinetilester minociklin HCl, i 9-metilglicinetilester minociklin. In one embodiment, R 9 is an alkyl glycine ethyl ester group. Exemplary tetracycline compounds with this R 9 substituent include 9-propylglycine ethyl ester minocycline HCl, and 9-methylglycine ethyl ester minocycline.
U jednom sastavnom dijelu, R9 je stiren skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(stiren) minociklin, 9-(4'-fluorostiren) minociklin. In one embodiment, R 9 is a styrene group. Exemplary tetracycline compounds with this R 9 substituent include 9-(styrene) minocycline, 9-(4'-fluorostyrene) minocycline.
U jednom sastavnom dijelu, R9 je tiofen skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(2-tiofen) minociklin, i 9-(5'-kloro-2'-tiofen) minociklin. In one embodiment, R 9 is a thiophene group. Exemplary tetracycline compounds with this R 9 substituent include 9-(2-thiophene) minocycline, and 9-(5'-chloro-2'-thiophene) minocycline.
U jednom sastavnom dijelu, R9 je alkilaminofosfo skupina. Primjer tetraciklinskih spojeva sa ovim R9 supstituentom uključuju 9-(p-metoksifenilaminofosfo) minociklin, i 9-(fenilaminofosfo) minociklin. In one embodiment, R 9 is an alkylaminophospho group. Exemplary tetracycline compounds with this R 9 substituent include 9-(p-methoxyphenylaminophospho) minocycline, and 9-(phenylaminophospho) minocycline.
Minociklinski spojevi iz ovog izuma mogu se sintetizirati upotrebljavajući metode opisane u Shemama 1-6. The minocycline compounds of this invention can be synthesized using the methods described in Schemes 1-6.
9-supstituirani minociklini mogu se sintetizirati slijedeći uobičajenu metodu, prikazanu u Shemi 1. 9-Substituted minocyclines can be synthesized following the usual method, shown in Scheme 1.
[image] [image]
SHEMA 1 SCHEME 1
Općenito, 9-supstituirani minociklinski spojevi mogu se sintetizirati kao što je pokazano u Shemi 2 tretirajući minociklin (1A), sa sulfatnom kiselinom i natrij nitratom. Rezultirajući produkt je 9-nitro (1B) minociklin. Nitro minociklinski spoj se tada tretira sa plinom vodika i platinskim katalizatorom da bi se dobio 9-amino minociklinski spoj, 1C. Da bi se sintetizirali 9 derivati, 9-amino minociklinski spoj se tretira sa HONO, da bi se dobila diazonijska sol (1D). Sol se nakon toga može tretirati sa brojnim spojevima koji sadrže alken ili funkcionalnu skupinu sa п vezom kao što su alkeni, arili, i alkinili (npr. R9Br) dobivajući 9-supstituirani minociklinski spoj (1E). In general, 9-substituted minocycline compounds can be synthesized as shown in Scheme 2 by treating minocycline (1A) with sulfuric acid and sodium nitrate. The resulting product is 9-nitro (1B) minocycline. The nitro minocycline compound is then treated with hydrogen gas and a platinum catalyst to give the 9-amino minocycline compound, 1C. To synthesize the 9 derivatives, the 9-amino minocycline compound is treated with HONO to give the diazonium salt (1D). The salt can then be treated with a number of compounds containing an alkene or p-bonded functional group such as alkenes, aryls, and alkynyls (eg R9Br) to give the 9-substituted minocycline compound (1E).
[image] [image]
SHEMA 2 SCHEME 2
Kao što je pokazano u Shemi 3, minociklinski spojevi iz izuma gdje je R9 derivat karbamata ili uree može se sintetizirati upotrebljavajući slijedeći protokol. Minociklin (2A) se tretira sa NaNO2 pod u kiselim uvjetima formirajući 9-nitro minociklin (2B). 9-nitrominociklin (2B) se tada tretira sa H2 plinom i platinskim katalizatorom da bi se formirao 9-amino minociklinski derivat (2C). Da bi se formirao derivat uree 2E), izocianat (2D) se reagira sa 9-amino minociklinskim derivatom (2C). Da bi se formirao karbamat (2G), odgovarajući kiseli klorid ester (2F) se reagira sa 2C. As shown in Scheme 3, minocycline compounds of the invention where R 9 is a carbamate or urea derivative can be synthesized using the following protocol. Minocycline (2A) is treated with NaNO2 under acidic conditions to form 9-nitro minocycline (2B). The 9-nitrominocycline (2B) is then treated with H2 gas and a platinum catalyst to form the 9-amino minocycline derivative (2C). To form the urea derivative 2E), the isocyanate (2D) is reacted with the 9-amino minocycline derivative (2C). To form the carbamate (2G), the corresponding acid chloride ester (2F) is reacted with 2C.
[image] [image]
SHEMA 3 SCHEME 3
Kao što je pokazano u Shemi 3, minociklinski spojevi iz izuma, gdje je R9 heterociklički spoj (npr. tiazol) supstituirana amino skupina se može sintetizirati koristeći gornji protokol. 9-amino minociklin (3A) se reagira sa Fmoc-izotiocianatom (3B) da bi producirao zaštićenu tioureu (3C). Zaštićena tiourea (3C) se tada odblokira dajući aktivni tetraciklin urea ili tetraciklin tiourea (3D) spoj. Tetraciklin tiourea (3D) se reagira sa α-haloketonom (3E) da bi producirala tiazol supstituirani 9-amino minociklin (3F). As shown in Scheme 3, minocycline compounds of the invention, where R 9 is a heterocyclic compound (eg thiazole) substituted amino group can be synthesized using the above protocol. 9-amino minocycline (3A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C). The protected thiourea (3C) is then unblocked to give the active tetracycline urea or tetracycline thiourea (3D) compound. Tetracycline thiourea (3D) is reacted with α-haloketone (3E) to produce thiazole substituted 9-amino minocycline (3F).
[image] [image]
SHEMA 4 SCHEME 4
Kao što je pokazano u Shemi 4, 9- alkenil minociklin spojevi (4A) se mogu hidrogenirati da formiraju alkil 9- supstituirane minociklinske spojeve (4B). Shema 4 pokazuje selektivnu hidrogenaciju dvostruke veze na 9- poziciji, sa plinom vodika i paladij/ugljik katalizatorom. Slično, 9-alkinil minociklini se također mogu hidrogenirati kako bi formirali 9-alkil minociklinske spojeve. As shown in Scheme 4, 9-alkenyl minocycline compounds (4A) can be hydrogenated to form alkyl 9-substituted minocycline compounds (4B). Scheme 4 shows the selective hydrogenation of the double bond at the 9-position, with hydrogen gas and a palladium/carbon catalyst. Similarly, 9-alkynyl minocyclines can also be hydrogenated to form 9-alkyl minocycline compounds.
[image] [image]
SHEMA 5 SCHEME 5
U Shemi 5, prikazana je općenita shema za sintetiziranje minociklinksih spojeva deriviranih na 9-poziciji arilom. U Shemi 5, prikazano je Suzuki spajanje aril borne kiseline sa jodominociklinskim spojem. Jodo minociklinski spoj(5B) se može sintetizirati iz sanciklina tretirajući minociklin (5A) sa barem jednim ekvivalentom N-jodosukcinimida (NIS) pod kiselim uvjetima. Reakcija je ugašena, a rezultirajući 9-jodo minociklin (5B) se tada može pročistiti upotrebljavajući standardne tehnike poznate u struci. Da bi se formirao aril derivat, 9-jodo minociklin (5B) se tretira sa bornom kiselinom (5C) plus vodenom otopinom natrij karbonata, i katalizira se sa paladijem. Produkt (5D) se može pročistiti pomoću metoda poznatih u struci (kao što je HPLC). Drugi 9-aril minociklinski spojevi se mogu sintetizirati upotrebljavajući slične protokole. In Scheme 5, a general scheme for synthesizing minocycline compounds derivatized at the 9-position with an aryl is shown. In Scheme 5, the Suzuki coupling of an aryl boronic acid with an iodominocycline compound is shown. The iodo minocycline compound (5B) can be synthesized from sancycline by treating minocycline (5A) with at least one equivalent of N-iodosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 9-iodo minocycline (5B) can then be purified using standard techniques known in the art. To form the aryl derivative, 9-iodo minocycline (5B) is treated with boric acid (5C) plus aqueous sodium carbonate, and catalyzed with palladium. The product (5D) can be purified using methods known in the art (such as HPLC). Other 9-aryl minocycline compounds can be synthesized using similar protocols.
9-supstituirani minociklinski spojevi iz izuma se također mogu sintetizirati upotrebljavajući Stille križna spajanja. Stille križna spajanja se može izvoditi upotrebljavajući prikladni kositreni reagens (npr. R-SnBu3) i halogenirani tetraciklinski spoj, (npr. 9-jodominociklin). Kositreni reagens i jodominociklinski spoj se mogu tretirati sa paladij katalizatorom (npr. Pd(PPh3)2Cl2 ili Pd(AsPh3)2Cl2) i, po izboru, sa dodatnom soli bakra, npr. CuI. Rezultirajući spoj se tada može pročistiti upotrebljavajući tehnike poznate u struci. The 9-substituted minocycline compounds of the invention can also be synthesized using Stille cross-couplings. Stille cross couplings can be performed using a suitable tin reagent (eg R-SnBu3) and a halogenated tetracycline compound, (eg 9-iodominocycline). The tin reagent and the iodominocycline compound can be treated with a palladium catalyst (eg Pd(PPh3)2Cl2 or Pd(AsPh3)2Cl2) and, optionally, with an additional copper salt, eg CuI. The resulting compound can then be purified using techniques known in the art.
[image] [image]
SHEMA 6 SCHEME 6
Spojevi iz izuma se također mogu sintetizirati koristeći Heck-tip reakcije križnog spajanja. Kao što je pokazano u Shemi 6, Heck-tip križno-spajanje se može izvoditi upotrebljavajući halogenirane tetraciklinske spojeve (npr. 9-jodominociklin, 6A), reaktivni alken (6B) ili alkin (6D), i prikladni paladij ili drugi prijelazni metal katalizator. Rezulirajući 9-supstituirani alkenil (6C) ili 9-supstituirani alkinil (6E) minociklinski spoj tada se može pročistiti upotrebljavajući tehnike poznate u struci. Compounds of the invention can also be synthesized using a Heck-type cross-coupling reaction. As shown in Scheme 6, Heck-type cross-coupling can be performed using halogenated tetracycline compounds (eg, 9-iodominocycline, 6A), a reactive alkene (6B) or alkyne (6D), and a suitable palladium or other transition metal catalyst . The resulting 9-substituted alkenyl (6C) or 9-substituted alkynyl (6E) minocycline compound can then be purified using techniques known in the art.
Izraz "alkil" uključuje zasičene alifatske skupine, uključujući ravno-lančane alkilne skupine (npr. metil, etil, propil, butil, pentil, heksil, heptil, oktil, nonil, decil, itd.), razgranato-lančane alkilne skupine (izopropil, tert-butil, izobutil, itd.), cikloalkilne (alicikličke) skupine (ciklopropil, ciklopentil, cikloheksil, cikloheptil, ciklooktil), alkil supstituirane cikloalkilne skupine, i cikloalkil supstituirane alkilne skupine. Izraz alkil nadalje uključuje alkilne skupine, koje mogu dalje uključivati kisik, dušik, sumpor ili fosfat atome koji zamjenjuju jedan ili više ugljika iz ugljikohidratnog kostura. U određenim sastavnim dijelovima, alkil sa ravnim ili razgranatim lancem ima 6 ili manje atoma ugljika u svom kosturu (npr. C1-C6 za ravni lanac, C3-C6 za razgranati lanac), a preferira se 4 ili manje. Isto tako, preferirajući cikloalkili imaju od 3-8 atoma ugljika u svojoj strukturi prstena, a više se preferira da imaju 5 ili 6 ugljika u strukturi prstena. Izraz C1-C6 uključuje alkil skupine koje sadrže 1 do 6 atoma ugljika. The term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (eg, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which may further include oxygen, nitrogen, sulfur or phosphate atoms replacing one or more carbons of the carbohydrate backbone. In certain embodiments, a straight or branched chain alkyl has 6 or fewer carbon atoms in its backbone (eg, C1-C6 for a straight chain, C3-C6 for a branched chain), with 4 or fewer being preferred. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, more preferably having 5 or 6 carbon atoms in their ring structure. The term C1-C6 includes alkyl groups containing 1 to 6 carbon atoms.
Štoviše, izraz alkil uključuje oboje "nesupstituirane alkile" i "supstituirane alkile", od kojih se posljednji odnosi na alkil jedinice koji imaju supstituente koji zamjenjuju vodik na jednom ili više ugljika iz ugljikohidratnog kostura. Takvi supstituenti mogu uključivati, na primjer alkenil, alkinil, halogen, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, arilkarbonil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfate, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatsku ili heteroaromatsku jedinicu. Cikloalkili mogu dalje biti supstituirani, npr. sa gore opisanim supstituentima. "Alkilaril" ili “arilalkil” jedinica je alkil supstituiran sa arilom (npr. fenilmetil (benzil)). Izraz “alkil” također uključuje postrane lance prirodnih i sintetskih aminokiselina. Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl units having substituents replacing hydrogen on one or more carbons of the carbohydrate backbone. Such substituents may include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, cyano, amino. (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro , trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit. Cycloalkyls can be further substituted, eg with the substituents described above. An "alkylaryl" or "arylalkyl" unit is an alkyl substituted with an aryl (eg, phenylmethyl (benzyl)). The term "alkyl" also includes the side chains of natural and synthetic amino acids.
Izraz "aril" uključuje skupine, uključujući 5- i 6-člane jedno-lančane aromatske skupine koje mogu uključivati od nula do četiri heteroatoma, na primjer benzen, fenil, pirol, furan, tiofen, tiazol, izotiaozol, imidazol, triazol, tetrazol, pirazol, oksazol, izooksazol, piridin, pirazin, piridazin, i pirimidin, i slično. Nadalje, izraz “aril” uključuje multicikličke aril skupine, npr. tricikličke, bicikličke, npr. naftalen, benzksazol, benzodioksazol, benzotiazol, benzoimidazol, benzotiofen, metilenedioksifenil, kvinolin, izokvinolin, naptridin, indol, benzofuran, purin, benzofuran, deazapurin, ili indolizin. Ove aril grupe koje imaju heteroatome u strukturi prstena mogu se također zvati i "aril heterociklički spojevi", “heterociklički spojevi”, "heteroarili" ili "heteroaromatski spojevi". Aromatski prsten može biti supstituiran na jednoj ili više pozicija prstena sa takvim supstituentima kao što su gore opisani, kao što su na primjer halogen, hidroksil, alkoksi, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkilaminoakarbonil, arilalkil aminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkilkarbonil, alkenilkarbonil, alkoksikarbonil, aminokarbonil, alkiltiokarbonil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfati, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatska ili heteroaromatska jedinica. Aril grupe mogu također biti srasle ili premošćene sa alicikličkim ili heterocikličkim prstenovima koji nisu aromatski tako da formiraju policiklički spoj (npr. tetralin). The term "aryl" includes groups including 5- and 6-membered single-chain aromatic groups which may include from zero to four heteroatoms, for example benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term “aryl” includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. These aryl groups having heteroatoms in the ring structure may also be called "aryl heterocyclic compounds", "heterocyclic compounds", "heteroaryls" or "heteroaromatic compounds". The aromatic ring may be substituted at one or more ring positions with such substituents as described above, such as, for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido); amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit. Aryl groups may also be fused or bridged with non-aromatic alicyclic or heterocyclic rings to form a polycyclic compound (eg tetralin).
Izraz "alkenil" uključuje nezasićene alifatske skupine analogne u duljini i mogućnosti supstitucije gore opisanim alkilima, ali koji sadrže barem jednu dvostruku vezu. The term "alkenyl" includes unsaturated aliphatic groups analogous in length and substitutability to the alkyls described above, but containing at least one double bond.
Na primjer izraz "alkenil" uključuje ravno-lančane alkenil skupine (npr. etilenil, propenil, butenil, pentenil, heksenil, heptenil, oktenil, nonenil, decenil, itd.), razgranato-lanačane alkenil skupine, cikloalkenil (alicikličke) skupine (ciklopropenil, ciklopentenil, cikloheksenil, cikloheptenil, ciklooktenil), alkil ili alkenil supstituirane cikloalkenil skupine, i cikloalkil ili cikloalkenil supstituirane alkenil skupine. Izraz alkenil nadalje uključuje alkenil skupine koje uključuju atome kisika, dušika, sumpora ili fosfora koji zamjenjuju jedan ili više ugljka iz ugljikohidratnog kostura. U određenim sastavnim dijelovima, ravno-lančana ili razgranato-lančana alkenil skupina ima 6 ili manje atoma ugljika u svom kosturu (npr. C2-C6 za ravni lanac, C3-C6 za razgranati lanac). Slično tome, cikloalkenil skupine mogu imati od 3-8 atoma ugljika u svojoj strukturi prstena, a više se preferira da imaju 5 ili 6 ugljika u strukturi prstena. Izraz C2-C6 uključuje alkenil skupine koje sadrže 2 do 6 atoma ugljika. For example, the term "alkenyl" includes straight-chain alkenyl groups (eg, ethyleneyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl , cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorus atoms replacing one or more carbons of the carbohydrate backbone. In certain moieties, a straight-chain or branched-chain alkenyl group has 6 or fewer carbon atoms in its backbone (eg, C2-C6 for a straight chain, C3-C6 for a branched chain). Similarly, cycloalkenyl groups can have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbon atoms in their ring structure. The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms.
Štoviše, izraz alkenil uključuje oboje "nesupstituirane alkenile" i "supstituirane alkenile", od kojih se posljednji odnosi na alkenil jedinice koji imaju supstituente koji zamjenjuju vodik na jednom ili više ugljka iz ugljikohidratnog kostura. Takvi supstituenti mogu uključivati, na primjer alkil skupine, alkinil skupine, halogene, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, arilkarbonil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfat, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatsku ili heteroaromatsku jedinicu. Moreover, the term alkenyl includes both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl units having substituents replacing hydrogen on one or more carbons of the carbohydrate backbone. Such substituents may include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, cyano , amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido , nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit.
Izraz "alkinil" uključuje nezasićene alifatske skupine analogne u duljini i mogućnosti supstitucije gore opisanim alkilima, ali koji sadrže barem jednu trostruku vezu. The term "alkynyl" includes unsaturated aliphatic groups analogous in length and substitutability to the alkyls described above, but containing at least one triple bond.
Na primjer izraz "alkinil" uključuje ravno-lančane alkinil skupine (npr. etinil, propinil, butinil, pentinil, heksinil, heptinil, oktinil, noninil, decinil, itd.), razgranato-lančane alkinil skupine, i cikloalkil ili cikloalkenil supstituirane alkinil skupine. Izraz alkinil nadalje uključuje alkinil skupine koje uključuju atome kisika, dušika, sumpora ili fosfora koji zamjenjuju jedan ili više ugljika iz ugljikohidratnog kostura. U određenim sastavnim dijelovima, ravno-lančana ili razgranato-lančana alkenil skupina ima 6 ili manje atoma ugljika u svom kosturu (npr. C2-C6 za ravni lanac, C3-C6 za razgranati lanac). Izraz C2-C6 uključuje alkenil skupine koje sadrže 2 do 6 atoma ugljika. For example, the term "alkynyl" includes straight-chain alkynyl groups (eg, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. . The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorus atoms replacing one or more carbons of the carbohydrate backbone. In certain moieties, a straight-chain or branched-chain alkenyl group has 6 or fewer carbon atoms in its backbone (eg, C2-C6 for a straight chain, C3-C6 for a branched chain). The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms.
Štoviše, izraz alkinil uključuje oboje "nesupstituirane alkinile" i "supstituirane alkinile", od kojih se posljednji odnosi na alkinil jedinice koji imaju supstituente koji zamjenjuju vodik na jednom ili više ugljka iz ugljikohidratnog kostura. Takvi supstituenti mogu uključivati, na primjer alkil skupine, alkinil skupine, halogene, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, arilkarbonil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfate, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatsku ili heteroaromatsku jedinicu. Moreover, the term alkynyl includes both "unsubstituted alkynyl" and "substituted alkynyl", the latter of which refers to alkynyl units having substituents replacing hydrogen on one or more carbons of the carbohydrate backbone. Such substituents may include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, cyano , amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido , nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit.
Osim ako je broj ugljika drugačije specificiran, "niži alkil" kao što je ovdje korišten znači alkil skupinu, kao što je gore definirana, ali koja ima od jednog do pet atoma ugljika u svojoj strukturi kostura. "Niži alkenil" i "niži alkinil" imaju dužinu lanaca od, na primjer, 2-5 atoma ugljika. Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms.
Izraz “acil” uključuje spojeve i jedinice koji sadrže acil radikal (CH3CO-) ili karbonil skupinu. Izraz “substituirani acil” uključuje acil skupine gdje su jedan ili više atoma vodika zamjenjeni sa na primjer alkil skupinama, alkinil skupinama, halogenima, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, arilkarbonil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfate, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatskom ili heteroaromatskom jedinicom. The term "acyl" includes compounds and units containing an acyl radical (CH3CO-) or a carbonyl group. The term "substituted acyl" includes acyl groups where one or more hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl. , alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio , thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit.
Izraz “acilamino” uključuje jedinice kod kojih je acil jedinica vezana uz amino skupinu. Na primjer izraz uključuje alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido skupine. The term “acylamino” includes units in which the acyl unit is attached to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
Izraz “aroil” uključuje spojeve i jedinice sa aril ili heteroaromatskom jedinicom vezanom uz karbonil skupinu. Primjeri aroil skupina uključuju fenilkarboksi, naftil karboksi, itd. The term "aroyl" includes compounds and units with an aryl or heteroaromatic unit attached to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthylcarboxy, etc.
Izrazi "alkoksialkil", "alkilaminoalkil" i "tioalkoksialkil" uključuju alkil skupine, kao što su gore opisane, koje nadalje uključuju atome kisika, dušika ili sumpora koji zamjenjuju jedan ili više ugljika iz ugljikohidratnog kostura, npr. atomi kisika, dušika ili sumpora. The terms "Alkoxyalkyl", "Alkylaminoalkyl" and "ThioAlkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the carbohydrate backbone, eg, oxygen, nitrogen or sulfur atoms.
Izraz “alkoksi” uključuje supstituirane i nesupstituirane alkil, alkenil, i alkinil skupine kovalentno vezane uz atom kisika. Primjeri alkoksi skupina uključuju metoksi, etoksi, izopropiloksi, propoksi, butoksi, i pentoksi skupine. Primjeri supstituiranih alkoksi skupina uključuju halogenirane alkoksi skupine. Alkoksi skupine mogu biti supstituirane sa skupinama kao što su alkenil, alkinil, halogen, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, arilkarbonil, alkoksikarbonil, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfate, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkilaril, ili aromatska ili heteroaromatska jedinica. Primjeri alkoksi skupina supstituiranih halogenom uključuju, ali nisu ograničeni na, fluorometoksi, difluorometoksi, trifluorometoksi, klorometoksi, diklorometoksi, triklorometoksi, itd. The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently bonded to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. Alkoxy groups may be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkyloxy, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic unit. Examples of halogen-substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.
Izraz “amin” ili “amino” uključuje spojeve u kojima je atom dušika kovalentno vezan za barem jedan ugljik ili heteroatom. Izraz “alkil amino” uključuje skupine i spojeve u kojima je dušik vezan uz barem jednu dodatnu alkil skupinu. Izraz “dialkil amino” uključuje skupine u kojima je atom dušika vezan uz barem dvije dodatne alkil skupine. Izraz “arilamino” i “diarilamino” uključuje skupine u kojima je dušik vezan uz barem jednu ili dvije aril skupine, pojedinačno. Izraz “alkilarilamino,” “alkilaminoaril” ili “arilaminoalkil” odnosi se na amino skupinu koja je vezana uz barem jednu alkil skupinu i barem jednu aril skupinu. Izraz “alkaminoalkil” odnosi se na alkil, alkenil, ili alkinil skupinu vezanu uz atom dušika koji je također vezan za alkil skupinu. The term “amine” or “amino” includes compounds in which the nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term "alkyl amino" includes groups and compounds in which the nitrogen is attached to at least one additional alkyl group. The term “dialkyl amino” includes groups in which the nitrogen atom is attached to at least two additional alkyl groups. The terms “arylamino” and “diarylamino” include groups in which the nitrogen is attached to at least one or two aryl groups, individually. The term "alkylarylamino," "alkylaminoaryl," or "arylaminoalkyl" refers to an amino group attached to at least one alkyl group and at least one aryl group. The term "alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group attached to a nitrogen atom that is also attached to an alkyl group.
Izraz “amid” ili “aminokarbonil” uključuje spojeve ili jedinice koje sadrže atom dušika koji je vezan za ugljik iz karbonil ili tiokarbonil skupine. Izraz uključuje “alkaminokarbonil” ili “alkilaminokarbonil” skupine koje uključuju alkil, alkenil, aril ili alkinil skupine vezane za amino skupinu koja je vezana za karbonil skupinu. To uključuje arilaminokarbonil skupine koje uključuju aril ili heteroaril jedinice vezane za amino skupinu koja je vezana za ugljik iz karbonil ili tiokarbonil skupine. Izrazi “alkilaminokarbonil,” “alkenilaminokarbonil,” “alkinilaminokarbonil,” “arilaminokarbonil,” “alkilkarbonilamino,” “alkenilkarbonilamino,” “alkinilkarbonilamino,” i “arilkarbonilamino” su uključeni u izraz “amid.” Amidi također uključuju urea skupine (aminokarbonilamino) i karbamate (oksikarbonilamino). The term “amide” or “aminocarbonyl” includes compounds or units containing a nitrogen atom attached to a carbon from a carbonyl or thiocarbonyl group. The term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups attached to an amino group which is attached to a carbonyl group. These include arylaminocarbonyl groups that include aryl or heteroaryl units attached to an amino group that is attached to the carbon of a carbonyl or thiocarbonyl group. The terms “alkylaminocarbonyl,” “alkenylaminocarbonyl,” “alkynylaminocarbonyl,” “arylaminocarbonyl,” “alkylcarbonylamino,” “alkenylcarbonylamino,” “alkynylcarbonylamino,” and “arylcarbonylamino” are included in the term “amide.” Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
Izraz “karbonil” ili “karboksi” uključuje spojeve i jedinice koje sadrže ugljik povezan dvostrukom vezom za atom kisika. Primjeri jedinica koji sadrže karbonil uključuju aldehide, ketone, karboksilne kiseline, amide, estere, anhidride, itd. The term “carbonyl” or “carboxy” includes compounds and units containing a carbon double bonded to an oxygen atom. Examples of carbonyl-containing units include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
Izraz “tiokarbonil” ili “tiokarboksi” uključuje spojeve i jedinice koji sadrže ugljik povezan dvostrukom vezom za atom sumpora. The term “thiocarbonyl” or “thiocarboxy” includes compounds and units containing a carbon double bonded to a sulfur atom.
Izraz “eter” uključuje spojeve ili jedinice koji sadrže kisik vezan za dva različita atoma ugljika ili heteroatoma. Na primjer izraz uključuje “alkoksialkil” koji se odnosi na alkil, alkenil, ili alkinil skupinu kovalentno vezanu na atom kisika koji je kovalentno vezan za drugu alkil skupinu. The term "ether" includes compounds or units containing oxygen attached to two different carbon atoms or heteroatoms. For example, the term includes “alkoxyalkyl” which refers to an alkyl, alkenyl, or alkynyl group covalently attached to an oxygen atom covalently attached to another alkyl group.
Izraz “ester” uključuje spojeve i jedinice koji sadrže ugljik ili heteroatom vezan za atom kisika koji je vezan za ugljik iz karbonil skupine. Izraz “ester” uključuje alkoksikarboksi skupine kao što su metoksikarbonil, etoksikarbonil, propoksikarbonil, butoksikarbonil, pentoksikarbonil, itd. Alkil, alkenil, ili alkinil skupine su kao što je gore definirano. The term "ester" includes compounds and units containing a carbon or heteroatom attached to an oxygen atom attached to a carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. Alkyl, alkenyl, or alkynyl groups are as defined above.
Izraz “tioeter” uključuje spojeve i jedinice koji sadrže atom sumpora vezan za dva različita ugljika ili hetero atoma. Primjeri tioetera uključuju, ali nisu ograničeni na alktioalkile, alktioalkenile, i alktioalkinile. Izraz “alktioalkili” uključuju spojeve sa alkil, alkenil, ili alkinil skupinu vezanu za atom sumpora koji je vezan za alkil skupinu. Slično, izraz “alktioalkenili” i “alktioalkinili” se odnosi na spojeve ili jedinice kod kojih je alkil, alkenil, ili alkinil skupina vezana za atom sumpora koji je kovalentno vezan za alkinil skupinu. The term "thioether" includes compounds and units containing a sulfur atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to, alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" includes compounds with an alkyl, alkenyl, or alkynyl group attached to a sulfur atom attached to the alkyl group. Similarly, the terms “alkthioalkenyls” and “alkthioalkynyls” refer to compounds or units in which an alkyl, alkenyl, or alkynyl group is attached to a sulfur atom that is covalently attached to the alkynyl group.
Izraz “hidroksi” ili “hidroksil” uključuje skupine sa –OH ili –O-. The term “hydroxy” or “hydroxyl” includes groups with –OH or –O-.
Izraz “halogen” uključuje fluorin, bromin, klorin, jodin, itd. Izraz “perhalogenirani” se općenito odnosi na jedinicu kod koje su svi atomi vodika zamjenjeni sa halogenim atomima. The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term "perhalogenated" generally refers to a unit in which all of the hydrogen atoms have been replaced by halogen atoms.
Izraz "policiklil" ili "policiklični radikal" odnosi se na dva ili više cikličnih prstenova (npr. cikloalkili, cikloalkenili, cikloalkinili, arili i/ili heterociklili) u kojima su dva ili više ugljika zajednička za dva granična prstena, npr., prsteni su "spojeni prsteni". Prsteni koji su povezani preko ne-susjednih atoma su označeni izrazom "premoščeni" prsteni. Svaki od prstena iz policikličkog spoja može biti supstituiran sa takvim supstituentima kao što su gore navedeni, kao na primjer halogen, hidroksil, alkilkarboniloksi, arilkarboniloksi, alkoksikarboniloksi, ariloksikarboniloksi, karboksilat, alkilkarbonil, alkoksikarbonil, alkilaminoakarbonil, arilalkilaminokarbonil, alkenilaminokarbonil, alkilkarbonil, arilkarbonil, arilalkil karbonil, alkenilkarbonil, aminokarbonil, alkiltiokarbonil, alkoksil, fosfat, fosfonato, fosfinato, cijano, amino (uključujući alkil amino, dialkilamino, arilamino, diarilamino, i alkilarilamino), acilamino (uključujući alkilkarbonilamino, arilkarbonilamino, karbamoil i ureido), amidino, imino, sulfhidril, alkiltio, ariltio, tiokarboksilat, sulfati, alkilsulfinil, sulfonato, sulfamoil, sulfonamido, nitro, trifluorometil, cijano, azido, heterociklil, alkil, alkilaril, ili aromatska ili heteroaromatska jedinica. The term "polycyclyl" or "polycyclic radical" refers to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, and/or heterocyclyls) in which two or more carbons are common to two terminal rings, e.g., the rings are "connected rings". Rings that are connected through non-adjacent atoms are called "bridged" rings. Each ring of the polycyclic compound may be substituted with such substituents as those listed above, such as halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl. carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic unit.
Izraz "heteroatom" uključuje atome bilo kojeg elementa osim ugljika ili vodika. Preferirani heteroatomi su dušik, kisik, sumpor i fosfor. The term "heteroatom" includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
Izraz “pred-lijek jedinica” uključuje jedinice koje se mogu metabolizirati in vivo do hidroksil skupine i jedinice koje mogu pogodno ostati esterificirane in vivo. Najradije, pred-lijek jedinice se metaboliziraju in vivo pomoću esteraza ili pomoću drugih mehanizama do hidroksil skupina ili drugih pogodnih skupina. Primjeri pred-lijekova i njihove upotrebe su dobro poznate u struci (Vidi, npr. Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). Pred-lijekovi se mogu pripremiti in situ za vrijeme krajnje izolacije i pročiščavanja spojeva, ili pomoću odvojenog reagiranja pročiščenog spoja u njegovom slobodnom kiselom obliku ili hidroksila sa pogodnim esterifikacijskim sredstvom. Hidroksil skupine se mogu promjeniti u estere pomoću obrade sa karboksilnom kiselinom. Primjeri pred-lijek jedinica uključuju supstitirane i nesupstituirane, razgranate i nerazgranate niže alkil ester jedinice, (npr. estere propionske kiseline), niže alkenil estere, di-niže alkil-amino niže-alkil estere (npr. dimetilaminoetil ester), acilamino niže alkil estere (npr. acetiloksimetil ester), aciloksi niže alkil estere (npr. pivaloiloksimetil ester), aril estere (fenil ester), aril-niže alkil estere (npr. benzil ester), supstituirane (npr. sa metil, halo, ili metoksi supstituentima) aril i aril-niže alkil estere, amide, niže-alkil amide, di-niže alkil amide, i hidroksi amide. Pred-lijek jedinice kojima se daje prednost su esteri propionske kiseline i acil esteri. The term “prodrug unit” includes units that can be metabolized in vivo to the hydroxyl group and units that can conveniently remain esterified in vivo. Preferably, the prodrug units are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other suitable groups. Examples of prodrugs and their uses are well known in the art (See, eg, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid or hydroxyl form with a suitable esterification agent. Hydroxyl groups can be changed to esters by treatment with carboxylic acid. Examples of prodrug units include substituted and unsubstituted, branched and unbranched lower alkyl ester units, (eg, propionic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (eg, dimethylaminoethyl ester), acylamino lower alkyl esters (e.g. acetyloxymethyl ester), acyloxy lower alkyl esters (e.g. pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g. benzyl ester), substituted (e.g. with methyl, halo, or methoxy substituents ) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug units are propionic acid esters and acyl esters.
Treba zabilježiti da struktura nekih od minociklinskih spojeva iz ovog izuma uključuje asimetrične atome ugljika. Prema tome se podrazumijeva da su izomeri koji nastaju iz takve asimetrije (npr. svi enantiomeri i diastereomeri) uključeni unutar područja ovog izuma, ukoliko nije drugačije naznačeno. Takvi izomeri se mogu dobiti u znatno čistom obliku pomoću klasičnih tehnika odvajanja i pomoću stereokemijski kontroliranih sinteza. Nadalje, strukture i drugi spojevi i jedinice o kojima se raspravlja u ovoj prijavi također uključuje sve tautomere istih. It should be noted that the structure of some of the minocycline compounds of this invention includes asymmetric carbon atoms. Accordingly, it is understood that isomers resulting from such asymmetry (eg, all enantiomers and diastereomers) are included within the scope of this invention, unless otherwise indicated. Such isomers can be obtained in substantially pure form using classical separation techniques and stereochemically controlled syntheses. Furthermore, the structures and other compounds and units discussed in this application also include all tautomers thereof.
Izum se također odnosi na metode za tretiranje stanja prijemljivih za tetraciklin u subjektima, pomoću primjene na subjektu efektivnog iznosa minociklinskog spoja iz izuma (npr. spoj iz Formule (I) ili prikazan u Tabeli 1), tako da se tretira stanje prijemljivo za tetraciklin. The invention also relates to methods for treating tetracycline-susceptible conditions in subjects, by administering to the subject an effective amount of a minocycline compound of the invention (eg, a compound of Formula (I) or shown in Table 1), so as to treat the tetracycline-susceptible condition.
Izraz “stanje prijemljivo za tetraciklinski spoj” uključuje stanja koja se mogu tretirati, spriječiti, ili drugačije popraviti pomoću primjene minociklinskog spoja iz izuma. Stanja prijemljiva za tetraciklinski spoj uključuju bakterijske infekcije (uključujući one koje su otporne na druge tetraciklinske spojeve), rak, dijabetes, i druga stanja za koje je nađeno da na njih djeluju tetraciklinski spojevi (vidi, na primjer U.S. Patent Br. 5,789,395; 5,834,450; i 5,532,227). Spojevi iz izuma mogu se koristiti za sprečavanje ili kontrolu značajnih bolesti sisavaca i veterinarskih bolesti kao što su dijareja, infekcije mokraćnog trakta, infekcije kože i kožne strukture, infekcije uha, grla i nosa, infekcije rana, mastitis i slično. Nadalje, uključene su također metode za tretiranje neoplazmi upotrebom tetraciklinskih spojeva iz izuma (van der Bozert et al., Cancer Res., 48:6686-6690 (1988)). Za određena stanja prijemljiva za tetraciklin, mogao bi biti poželjan minociklinksi spoj iz izuma sa malo ili bez antibakterijske aktivnosti. The term "a condition susceptible to a tetracycline compound" includes conditions that can be treated, prevented, or otherwise ameliorated by administration of a minocycline compound of the invention. Conditions susceptible to a tetracycline compound include bacterial infections (including those resistant to other tetracycline compounds), cancer, diabetes, and other conditions that have been found to be responsive to tetracycline compounds (see, for example, U.S. Patent Nos. 5,789,395; 5,834,450; and 5,532,227). The compounds of the invention can be used to prevent or control significant mammalian and veterinary diseases such as diarrhea, urinary tract infections, skin and skin structure infections, ear, throat and nose infections, wound infections, mastitis and the like. Furthermore, methods for treating neoplasms using the tetracycline compounds of the invention are also included (van der Bozert et al., Cancer Res., 48:6686-6690 (1988)). For certain conditions susceptible to tetracycline, a minocycline compound of the invention with little or no antibacterial activity may be preferred.
Velik broj različitih gram pozitivnih i gram negativnih bakterija mogu prouzročiti bakterijske infekcije. Spojevi iz izuma su korisni kao antibiotici protiv organizama koji su otporni na duge tetraciklinske spojeve. Antibiotska aktivnost tetraciklinskih spojeva iz izuma se može odrediti koristeći metode opisane u Primjeru 2, ili koristeći in vitro standardnu metodu sa otopinom bujona opisanu u Waitz, J.A., National Commission for Clinical Laboratory Standards, Document M7-A2, vol. 10, no. 8, pp. 13-20, 2nd edition, Villanova, PA (1990). A large number of different gram positive and gram negative bacteria can cause bacterial infections. The compounds of the invention are useful as antibiotics against organisms that are resistant to long tetracycline compounds. The antibiotic activity of the tetracycline compounds of the invention can be determined using the methods described in Example 2, or using the in vitro standard broth method described in Waitz, J.A., National Commission for Clinical Laboratory Standards, Document M7-A2, vol. 10, no. 8, pp. 13-20, 2nd edition, Villanova, PA (1990).
Minociklinksi spojevi se također mogu koristiti za tretiranje infekcija koje se tradicionalno tretiraju sa tetraciklinskim spojevima kao što su, na primjer riketsije; brojne gram-positivne i gram-negativne bakterije; i uzročnici odgovorni za venerični limfogranulom, inkluzijski konjuktivitis, psitakozu. Tetraciklinski spojevi se mogu koristiti za tretiranje infekcija od npr. K. pneumoniae, Salmonella, E. hirae, A. baumanii, B. catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus ili E. faecalis. U jednom sastavnom dijelu, minociklinklsi spoj se koristi za tretiranje bakterijske infekcije koja je otporna na druge tetraciklinske antibiotske spojeve. Minociklinksi spoj iz izuma se može primjeniti sa farmaceutski prihvatljivim nosačem. Minocycline compounds can also be used to treat infections traditionally treated with tetracycline compounds such as, for example, rickettsiae; numerous gram-positive and gram-negative bacteria; and causative agents responsible for venereal lymphogranuloma, inclusion conjunctivitis, psittacosis. Tetracycline compounds can be used to treat infections caused by, for example, K. pneumoniae, Salmonella, E. hirae, A. baumanii, B. catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus or E faecalis. In one component, a minocycline compound is used to treat a bacterial infection that is resistant to other tetracycline antibiotic compounds. The minocycline compound of the invention can be administered with a pharmaceutically acceptable carrier.
Izraz "djelotvorna količina" spoja znači ona količina neophodna ili dovoljna za tretiranje ili prevenciju stanja prijemljivog za tetraciklinksi spoj. Djelotvorna količina može varirati ovsino o takvim faktorima kao što su veličina i težina subjekta, tip bolesti, ili o konkretnom minociklinksom spoju. Na primjer, izbor minociklinksog spoja može utjecati što čini "djelotvornu količinu". Stručnjak u tom području bi trebao biti sposoban proučiti prije spomenute faktore i donjeti odluku glede djelotvorne količine minociklinskog spoja bez pretjeranog eksperimentiranja. The term "effective amount" of a compound means that amount necessary or sufficient to treat or prevent a condition susceptible to the tetracycline compound. The effective amount may vary depending on such factors as the size and weight of the subject, the type of disease, or the particular minocycline compound. For example, the choice of minocycline compound can affect what constitutes an "effective amount". One skilled in the art should be able to examine the aforementioned factors and make a decision regarding an effective amount of minocycline compound without undue experimentation.
Izum se također odnosi na metode tretmana protiv infekcija mikroorganizama i pridruženih bolesti. Metode uključuju davanje djelotvorne količine jednog ili više minociklinskih spojeva subjektu. Subjekt može biti biljka, ili povoljnije, životinja, npr. sisavac, npr. čovjek. The invention also relates to methods of treatment against microorganism infections and associated diseases. The methods include administering to a subject an effective amount of one or more minocycline compounds. The subject can be a plant, or preferably an animal, eg a mammal, eg a human.
U terapeutskim metodama iz izuma, jedan ili više minociklinksih spojeva iz izuma se može davati samo subjektu, ili uobičajenije spoj iz izuma će se dati kao dio farmaceutske smjese sa uobičajenim ekscipijentom, npr. farmaceutski prihvatljivim organskim ili anorganskim tvarima nosača prikladnih za parenteralnu, oralnu ili drugu željenu primjenu i koje ne reagiraju štetno sa aktivnim spojevima i nisu štetni za recipijenta istih. In the therapeutic methods of the invention, one or more minocycline compounds of the invention may be administered alone to the subject, or more commonly the compound of the invention will be administered as part of a pharmaceutical mixture with a conventional excipient, e.g., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired application and which do not react harmfully with the active compounds and are not harmful to the recipient thereof.
Izum se također odnosi na farmaceutske smjese koje sadrže terapeutski djelotvorne količine minociklinskog spoja i, po izboru, farmaceutski prihvatljiv nosač. The invention also relates to pharmaceutical compositions containing therapeutically effective amounts of a minocycline compound and, optionally, a pharmaceutically acceptable carrier.
Izraz "farmaceutski prihvatljiv nosač" uključuje tvari koje se mogu primjenjivati zajedno sa minociklinskim spojem (spojevima), i koje im oboma dopuštaju da izvedu njihovu namjenjenu funkciju, npr. da liječe ili spriječe stanje prijemljivo za tetraciklin. Prikladni farmaceutski prihvatljivi nosači uključuju, ali nisu ograničeni na vodu, otopine soli, alkohol, biljna ulja, polietilen glikole, želatinu, laktozu, amilozu, magnezij stearat, talk, silikatnu kiselina, viskozni parafin, eterična ulja, monogliceride i digliceride masnih kiselina, estere petroetralne masne kiseline, hidroksimetil-celuloza, polivinilpirolidon, itd. Farmaceutski preparati se mogu sterilizirati i po želji pomiješati sa pomoćnim sredstvima, npr. mazivima, konzervansima, stabiliziatorima, sredstvima za vlaženje, emulgatorima, solima za utjecanje na osmotski tlak, puferima, bojama, aromama i/ili aromatičnim tvarima i slično, koje ne reagiraju štetno sa aktivnim spojevima iz izuma. The term "pharmaceutically acceptable carrier" includes substances which can be administered together with the minocycline compound(s), and which allow both to perform their intended function, eg to treat or prevent a tetracycline-susceptible condition. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, essential oils, monoglycerides and diglycerides of fatty acids, esters petroether fatty acids, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. Pharmaceutical preparations can be sterilized and optionally mixed with auxiliaries, e.g. lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, dyes, aromas and/or aromatic substances and the like, which do not react harmfully with the active compounds from the invention.
Minociklinski spojevi koji su bazne prirode, sposobni su formirati velik broj soli sa raznim anorganskim i organskim kiselinama. Kiseline koje se mogu koristiti za pripremu farmaceutski prihvatljivih soli minociklinskih spojeva iz izuma koji su bazne prirode su one koje tvore netoksične soli adicijom kiseline, npr. soli koje sadrže farmaceutski prihvatljive anione, kao što su hidroklorid, hidrobromid, hidrojodid, nitrat, sulfat, bisulfat, fosfat, kiseli fosfat, izonikotinat, acetat, laktat, salicilat, citrat, kiseli citrat, tartrat, pantotenat, bitartrat, askorbat, sukcinat, maleat, gentisinat, fumarat, glukonat, glukaronat, saharat, format, benzoat, glutamat, metanesulfonat, etansulfonat, benzensulfonat, p-toluenesulfonat i palmoat [npr. 1,1'-metilen-bis-(2-hidroksi-3-naftoat)] soli. Iako takve soli moraju biti farmaceutski prihvatljive za davanje subjektu, npr. sisavcu, često je poželjno u praksi početno izolirati minociklinski spoj iz izuma iz reakcijske smjese kao farmaceutski neprihvatljive soli i tada jednostavno obratiti natrag do slobodnog baznog spoja tretmanom sa alkalnim reagensom te kasnije obratiti slobodnu bazu do farmaceutski prihvatljive soli adicijom kiseline. Soli adicijom kiseline na bazne spojeve iz ovog izuma pripremaju se tretirajući bazni spoj sa temeljno ekvivalentnom količinom izabrane mineralne ili organske kiseline u mediju vodene otopine ili u prikladnom organskom otapalu, kao što su metanol ili etanol. Nakon pažljivog isparavanja otapala, dobiva se željena kruta sol. Priprema drugih minociklinskih spojeva iz izuma koja nije opisana u prije prikazanom eksperimentalnom dijelu može se postići koristeći kombinacije gore opisanih reakcija što će stručnjacima biti očito. Minocycline compounds, which are basic in nature, are capable of forming a large number of salts with various inorganic and organic acids. Acids which can be used to prepare pharmaceutically acceptable salts of the minocycline compounds of the invention which are basic in nature are those which form non-toxic salts by acid addition, eg salts containing pharmaceutically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate , phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate , benzenesulfonate, p-toluenesulfonate and palmoate [e.g. 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to a subject, e.g. a mammal, it is often desirable in practice to initially isolate the minocycline compound of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert back to the free base compound by treatment with an alkaline reagent and later convert the free base to a pharmaceutically acceptable salt by acid addition. Acid addition salts of base compounds of this invention are prepared by treating the base compound with a substantially equivalent amount of a selected mineral or organic acid in an aqueous solution medium or in a suitable organic solvent, such as methanol or ethanol. After careful evaporation of the solvent, the desired solid salt is obtained. The preparation of other minocycline compounds of the invention not described in the previously presented experimental section can be achieved using combinations of the reactions described above as will be apparent to those skilled in the art.
Minociklinski spojevi iz izuma koji su kisele prirode, sposobni su formirati velik broj baznih soli. Kemijske baze koje se mogu koristiti kao reagensi za pripremanje farmaceutski prihvatljivih baznih soli onih minociklinskih spojeva koji su kisele prirode su one koji formiraju netoksične bazne soli sa tim spojevima. Takve netoksične bazne soli uključuju, ali nisu ograničeni na one derivirane iz takvih farmaceutski prihvatljivih kationa kao što su kationi alkalnih metala (npr. kalij i natrij) i kationi zemno alkalijskih metala (npr. kalcij i magnezij), amonij ili topive u vodi soli adicijom amina kao što su N-metilglukamin-(meglumin), i niži alkanolamonij i druge bazne soli farmaceutski prihvatljivih organskih amina. Farmaceutski prihvatljive soli adicijom baze na minociklinske spojeve koji su kisele prirode mogu se formirati sa farmaceutski prihvatljivim kationima pomoću uobičajenih metoda. Tako se ove soli mogu lako prirediti tretirajući minociklinski spoj iz izuma sa vodenom otopinom željenog farmaceutski prihvatljivog kationa i evaporirajući rezultirajuću otopinu dok se ne osuši, po mogućnosti pod reduciranim tlakom. Alternativno, otopina minociklinskog spoja iz izuma u nižem alkil alkoholu se može pomiješati sa alkoksidom željenog metala, nakon čega se otopina evaporira dok se ne osuši. The minocycline compounds of the invention, which are acidic in nature, are capable of forming a large number of base salts. Chemical bases that can be used as reagents for the preparation of pharmaceutically acceptable base salts of those minocycline compounds which are acidic in nature are those which form non-toxic base salts with these compounds. Such non-toxic base salts include, but are not limited to, those derived from such pharmaceutically acceptable cations as alkali metal cations (eg, potassium and sodium) and alkaline earth metal cations (eg, calcium and magnesium), ammonium, or water-soluble salts by addition amines such as N-methylglucamine-(meglumine), and lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. Pharmaceutically acceptable base addition salts of minocycline compounds which are acidic in nature can be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts can be readily prepared by treating the minocycline compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a solution of the minocycline compound of the invention in a lower alkyl alcohol may be mixed with the alkoxide of the desired metal, after which the solution is evaporated to dryness.
Priprema drugih minociklinskih spojeva iz izuma koja nije opisana u prije prikazanom eksperimentalnom dijelu može se postići koristeći kombinacije gore opisanih reakcija što će stručnjacima biti očito. The preparation of other minocycline compounds of the invention not described in the previously presented experimental section can be achieved using combinations of the reactions described above as will be apparent to those skilled in the art.
Minociklinski spojevi iz izuma i njihove farmaceutski prihvatljive soli se mogu davati oralnim, parenteralnim ili topikalnim putem. Općenito, najpoželjnije je ove spojeve davati u djelotvornim dozama, ovisno o težini i stanju subjekta koji se tretira i o konkretnom izabranom putu davanja. Mogu se pojaviti varijacije ovisno o vrsti subjekta kojeg se tretira i o njegovoj individualnoj reakciji na navedeni lijek, kao i o tipu izabrane farmaceutske formulacije i o vremenskom periodu i intervalu u kojemu je takvo davanje izvršeno. The minocycline compounds of the invention and their pharmaceutically acceptable salts can be administered orally, parenterally or topically. In general, it is most preferred to administer these compounds in effective doses, depending on the weight and condition of the subject being treated and the particular route of administration chosen. Variations may occur depending on the type of subject being treated and on his individual reaction to said drug, as well as on the type of pharmaceutical formulation chosen and on the time period and interval in which such administration is performed.
Farmaceutska smjesa iz izuma se može davati sama ili u kombinaciji sa drugim poznatim smjesama za tretiranje stanja prijemljivih za tetraciklin u subjektu, npr. sisavcu. Preferirajući sisavci uključuju kućne ljubimce (npr. mačke, pse, kune, itd.), domaće životinje (krave, ovce, svinje, konje, koze, itd.), laboratorijske životinje (štakore, miševe, majmune, itd.) i primate (čimpanze, ljude, gorile). Izraz “u kombinaciji sa” poznatom smjesom uključuje simultano davanje smjese iz izuma i poznate smjese, davanje smjese iz izuma prve, slijedeći sa poznatom smjesom, i davanje poznate smjese prve, slijedeći sa smjesom iz izuma. Bilo koja terapeutska smjesa poznata struci za tretiranje stanja prijemljivih na tetraciklin se može koristiti u metodama iz izuma. The pharmaceutical composition of the invention may be administered alone or in combination with other known compositions for the treatment of tetracycline-susceptible conditions in a subject, e.g., a mammal. Preferred mammals include pets (eg, cats, dogs, martens, etc.), domestic animals (cows, sheep, pigs, horses, goats, etc.), laboratory animals (rats, mice, monkeys, etc.), and primates ( chimpanzees, humans, gorillas). The term "in combination with" a known mixture includes the simultaneous administration of the mixture of the invention and the known mixture, the administration of the mixture of the invention first, followed by the known mixture, and the administration of the known mixture first, followed by the mixture of the invention. Any therapeutic composition known in the art for treating conditions susceptible to tetracycline can be used in the methods of the invention.
Minociklinski spojevi iz izuma se mogu davati sami ili u kombinaciji sa farmaceutski prihvatljivim nosačima ili razređivačima bilo kojim prije spomenutim putem, i davanje se može izvoditi u pojedinačnim ili višestrukim dozama. Na primjer, novo terapeutsko sredstvo iz ovog izuma se može korisno davati u velikom broju različitih oblika doziranja, npr. mogu se kombinirati sa raznim farmaceutski prihvatljivim inertnim nosačima u obliku tableta, kapsula, pastila, troheja, tvrdih bombona, praha, sprejeva, krema, melema, supozitorija, želea, gelova, pasta, losiona, masti, vodenih otopina, otopina za injekcije, eliksira, sirupa, i slično. Takvi nosači uključuju krute razblaživače ili punila, sterilni vodeni medij i brojna neotrovna organska otapala, itd. Štoviše, oralne farmaceutske smjese se mogu prikladno zasladiti i/ili dodati arome. Općenito, terapeutski djelotvorni spojevi iz ovog izuma su prisutni u takvim oblicima doziranja u razinama koncentracije od oko 5.0% do oko 70% po težini. The minocycline compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the aforementioned routes, and administration may be carried out in single or multiple doses. For example, the novel therapeutic agent of this invention may be usefully administered in a wide variety of dosage forms, e.g., may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, lozenges, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous solutions, solutions for injections, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media, and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions may be suitably sweetened and/or flavored. Generally, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels of from about 5.0% to about 70% by weight.
Za oralnu primjenu, tablete koje sadrže razne ekscipijente kao što su mikrokristalična celuloza, natrij citrat, kalcij karbonat, dikalcij fosfat i glicin mogu se koristiti zajedno sa raznim sredstima za dezintegraciju kao što su škrob (poželjno škrob kukuruza, krumpira ili tapioke), alginska kiselina i određeni složeni silikati, zajedno sa granulacijskim vezivom kao što su polivinilpirolidon, saharoza, želatina i akacija. Dodatno, sredstva za podmazivanje kao što su magnezij stearat, natrij lauril sulfat i talk su često vrlo koristna za svrhe tabletiranja. Krute smjese sličnog tipa mogu se također koristiti kao punila u želatinskim kapsulama; poželjne tvari za ovu svrhu također uključuju laktozu ili mliječni šečer kao i polietilen glikole visoke molekularne mase. Kada se za oralnu primjenu žele vodene otopine i/ili eliksiri, aktivni sastojak se može kombinirati različitim sredstvima za zaslađivanje ili dodavanje okusa, bojama, i po želji također sredstvima za emulgiranje i/ili suspenziranje, zajedno sa takvim otapalima kao što su voda, etanol, propilen glikol, glicerin i mnoge slične kombinacije istih. For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine can be used together with various disintegrants such as starch (preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with a granulation binder such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricants such as magnesium stearate, sodium lauryl sulfate, and talc are often very useful for tableting purposes. Solid mixtures of a similar type can also be used as fillers in gelatin capsules; preferred substances for this purpose also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous solutions and/or elixirs are desired for oral administration, the active ingredient can be combined with various sweetening or flavoring agents, colors, and optionally also emulsifying and/or suspending agents, together with such solvents as water, ethanol , propylene glycol, glycerin and many similar combinations thereof.
Za parenteralnu primjenu (uključujući intraperitonealnu, subkutanu, intravenoznu, intradermalnu ili intramuskularnu injekciju), mogu se koristiti otopine terapeutskog spoja iz ovog izuma u sezamovu ili kikirikijevom ulju ili u vodenoj otopini propilen glikola. Vodene otopine ako je potrebno trebaju biti prikladno puferirane (poželjno pH veći 8) a tekuće otapalo prvo izotonično pripremljeno. Ove vodene otopine su prikladne za svrhu intravenoznih injekcija. Uljne otopine su prikladne za svrhu intraartikularnih, intramuskularnih i subkutanih injekcija. Priprema svih ovih otopina pod sterilnim uvjetima lako se postiže standardnim farmaceutskim tehnikama dobro poznatim stručnjacima u ovom području. Za parenteralnu primjenu, primjeri prikladnih preparata uključuju otopine, poželjno uljne ili vodene otopine kao i suspenzije, emulzije, ili implante, uključujući supozitorije. Terapeutski spojevi mogu biti formulirani u sterilnom obliku u višestrukim ili jednostrukim dozama disperzirani u tekućem nosaču kao što je sterilna slana fiziološka otopina ili 5% slana otopina dekstroze koje se obično koriste kod injekcija. For parenteral administration (including intraperitoneal, subcutaneous, intravenous, intradermal, or intramuscular injection), solutions of a therapeutic compound of the present invention in sesame or peanut oil or in aqueous propylene glycol can be used. Aqueous solutions, if necessary, should be suitably buffered (preferably pH higher than 8) and the liquid solvent first prepared isotonically. These aqueous solutions are suitable for the purpose of intravenous injections. Oil solutions are suitable for the purpose of intra-articular, intramuscular and subcutaneous injections. Preparation of all of these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. For parenteral administration, examples of suitable preparations include solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compounds may be formulated in sterile form in multiple or single doses dispersed in a liquid vehicle such as sterile saline or 5% dextrose saline commonly used for injection.
Nadalje, također je moguće primjenjivati spojeve iz ovog izuma topikalno kod tretiranja upalnih stanja kože. Primjeri metoda topikalne primjene uključuju transdermalnu, bukalnu ili sublingualnu primjenu. Za topikalnu primjenu, terapeutski spojevi se mogu prikladno pomiješati u farmakološko inertnom topikalnom nosaču kao što je gel, mast, losion ili krema. Takvi topikalni nosači uključuju vodu, glicerol, alkohol, propilen glikol, masne alkohole, trigliceride, estere masnih kiselina, ili mineralna ulja. Drugi mogući topikalni nosači su tekući parafin, izopropilpalmitat, polietilen glikol, etanol 95%, polioksietilen monolauriat 5% u vodi, natrij lauril sulfat 5% u vodi, i slično. Nadalje, tvari kao što su antioksidansi, sredstva za vlaženje, stabilizatori viskoznosti i slično također se mogu po želji dodavati. Furthermore, it is also possible to apply the compounds of this invention topically in the treatment of inflammatory conditions of the skin. Examples of topical administration methods include transdermal, buccal, or sublingual administration. For topical administration, the therapeutic compounds may be conveniently admixed in a pharmacologically inert topical carrier such as a gel, ointment, lotion or cream. Such topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid paraffin, isopropyl palmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolaurate 5% in water, sodium lauryl sulfate 5% in water, and the like. Furthermore, substances such as antioxidants, wetting agents, viscosity stabilizers and the like may also be added as desired.
Za enteralnu primjenu, naročito su prikladne tablete, dražeje ili kapsule koje imaju talk i/ili ugljikohidratni vezivni nosač ili slično, gdje je poželjno da nosač bude laktoza i/ili kukuruzni škrob i/ili krumpirov škrob. Sirup, eliksir ili slično se može koristiti kada se upotrebljava sredstvo za zaslađivanje. Mogu se formulirati smjese sa zadržanim oslobađanjem uključujući one gdje je aktivna komponenta zaštićena sa različito razgradivim omotačima, npr. pomoću mikrokapsulacije, mnogostrukim omotačima, itd. For enteral administration, tablets, dragees or capsules that have talc and/or a carbohydrate binding carrier or the like are particularly suitable, where it is preferable that the carrier is lactose and/or corn starch and/or potato starch. A syrup, elixir or similar can be used when a sweetening agent is used. Sustained release compositions can be formulated including those where the active component is protected with differently degradable coatings, eg by microencapsulation, multiple coatings, etc.
Pored tretmana ljudskih subjekata, terapeutske metode iz izuma će također imati značajne veterinarske primjene, npr. za tretman stoke kao što ovce, koze, krave, svinje i slično; peradi kao što su kokoši, patke, guske, purani i slično; konja; i kučnih ljubimaca kao što su psi i mačke. Također, spojevi iz izuma se mogu koristiti za tretman ne-životinjskih subjekata, kao što su biljke. In addition to the treatment of human subjects, the therapeutic methods of the invention will also have significant veterinary applications, eg for the treatment of livestock such as sheep, goats, cows, pigs and the like; poultry such as chickens, ducks, geese, turkeys and the like; horse; and pets such as dogs and cats. Also, the compounds of the invention can be used to treat non-animal subjects, such as plants.
Treba se uzeti u obzir da će točne poželjne količine aktivnih sastojaka koji se koriste u datoj terapiji varirati ovisno o specifičnom spoju koji se koristi, konkretnoj formulaciji smjese, načinu primjene, određenom mjestu primjene, itd. Optimalni iznosi primjene za zadani protokol primjene stručnjaci u području mogu lako utvrditi koristeći konvenciolne testove određivanja doza izvođenih u skladu sa gore navedenim smjernicama. It should be noted that the exact desired amounts of active ingredients used in a given therapy will vary depending on the specific compound used, the particular formulation of the mixture, the route of administration, the particular site of administration, etc. The optimal amounts of administration for a given administration protocol will be determined by those skilled in the art. can be easily determined using conventional dose determination tests performed according to the above guidelines.
Općenito, spojevi iz izuma se za tretman mogu primjenjivati na subjektu u dozama koje su se koristile u prošlim minociklinskim terapijama. Vidjeti, na primjer “Physicians' Desk Reference”. Na primjer, prikladna djelotvorna doza jednog ili više spojeva iz izuma će biti u rasponu od 0.01 do 100 miligrama po kilogramu tjelesne mase recipijenta po danu, poželjno u rasponu od 0.1 do 50 miligrama po kilogramu tjelesne mase recipijenta po danu, još poželjnije u rasponu od 1 to 20 miligrama po kilogramu tjelesne mase recipijenta po danu. Željena doza se prikladno primjenjuje jednom dnevno, ili u nekoliko sub-doza, npr. 2 do 5 sub-doza, koje se primjenjuju u prikladnim intervalima kroz dan, ili po drugom prikladnom rasporedu. In general, the compounds of the invention can be administered to a subject for treatment at doses that have been used in past minocycline therapies. See, for example, "Physicians' Desk Reference". For example, a suitable effective dose of one or more compounds of the invention will be in the range of 0.01 to 100 milligrams per kilogram of the recipient's body weight per day, preferably in the range of 0.1 to 50 milligrams per kilogram of the recipient's body weight per day, more preferably in the range of 1 to 20 milligrams per kilogram of body weight of the recipient per day. The desired dose is conveniently administered once daily, or in several sub-doses, eg 2 to 5 sub-doses, administered at convenient intervals throughout the day, or on another convenient schedule.
Podrazumijeva se također da se trebaju koristiti normalne, uobičajene mjere opreza u vezi uzimanja minociklina općenito da bi se osigurala njihova efikasnost pod normalnim okolnostima uzimanja. Pogotovo kada se koriste za terapeutski tretman ljudi i životinja in vivo, liječnik treba poduzeti sve razumne mjere opreza da se izbjegnu uobičajeno poznate kontradikcije i toksični efekti. Tako, uobičajeno poznate štetne reakcije gastrointestinalne boli i upala, renalna toksičnost, reakcije hipersenzitivnosti, promjene u krvi, i slabljenje apsorpcije putem iona aluminija, kalcija, i magnezija bi se trebale propisno razmotriti na uobičajeni način. It is also understood that normal, usual precautions should be taken with minocycline in general to ensure its effectiveness under normal circumstances of administration. Especially when used for the therapeutic treatment of humans and animals in vivo, the physician should take all reasonable precautions to avoid commonly known contradictions and toxic effects. Thus, commonly known adverse reactions of gastrointestinal pain and inflammation, renal toxicity, hypersensitivity reactions, blood changes, and impaired absorption by aluminum, calcium, and magnesium ions should be properly considered in the usual manner.
U jednom sastavnom dijelu, minociklinski spojevi iz izuma ne uključuju one opisane u U.S. Patent Prijavi serijski Broj 09/823,884, uključene ovdje referencom. In one embodiment, the minocycline compounds of the invention do not include those described in U.S. Pat. Patent Application Serial Number 09/823,884, incorporated herein by reference.
Nadalje, izum se također odnosi na upotrebu minociklinskog spoja iz Formule I ili II, za pripremanje lijeka. Lijek može uključivati farmaceutski prikladan nosač i djelotvornu količinu minociklinskog spoja, npr. djelotvornu količinu za tretiranje stanja prijemljivog za tetraciklin. Furthermore, the invention also relates to the use of a minocycline compound of Formula I or II, for the preparation of a medicament. The medicament may include a pharmaceutically acceptable carrier and an effective amount of a minocycline compound, eg, an effective amount to treat a tetracycline-susceptible condition.
Ilustracija izuma Illustration of the invention
Spojevi iz izuma se mogu napraviti kao što je dolje opisano, sa mogućim promijenama dolje opisanih postupaka koje su uobičajene stručnjacima iz struke. The compounds of the invention may be made as described below, with possible modifications to the procedures described below which are common to those skilled in the art.
Primjer 1: Priprema Minociklinskih Spojeva iz Izuma Example 1: Preparation of Minocycline Compounds of the Invention
Priprema 9-Jodominociklina Preparation of 9-Iodominocycline
U 200ml 97% metansulfonske kiseline je polako dodano, pri sobnoj temperaturi, udio [30g;56.56mM] minociklin-bis-hidroklorid soli. Tamna žuto smeđa otopina je miješana pri sobnoj temperaturi dok se dodavalo [38g;169.7mM] N-jodosukcinimida, u šest jednakih obroka, tijekom više od 3.0 sata vremena. Reakcija se promatrala putem analitičkog LC-a, bilježeći nestajanje početne tvari. In 200ml of 97% methanesulfonic acid, a portion of [30g; 56.56mM] minocycline bis-hydrochloride salt was added slowly, at room temperature. The dark tan solution was stirred at room temperature while [38g;169.7mM] N-iodosuccinimide was added, in six equal portions, over a period of over 3.0 hours. The reaction was monitored by analytical LC, recording the disappearance of the starting substance.
Reakcija je polako ugašena sa 2l ledeno hladne vode koja sadrži [17.88g;1134.1mM] natrij tiosulfata sa snažnim miješanjem otprilike 30 minuta pri sobnoj temperaturi. Vodeni sloj je tada ekstrahiran sa 6x200ml etil acetata prije što je vodeni sloj naliven na [259.8g;3.08M] natrij hidrogen karbonata koji sadrži 300ml n-butanola. Faze su razdvojene i vodena ekstrahirana sa 4x250ml n-butanola. Organske frakcije su udružene i isprane sa 3x250ml vode i jednom sa 250ml zasičenog rasola. Rezultirajuća organska faza je tada reducirana do suhog stanja pod smanjenim pritiskom. Ostatak je suspenziran u metanolu (~600ml) i anhidrirani HCl plin je uveden u ovu mješavinu dok se nije pojavila otopina. Ova otopina je reducirana do suhog stanja pod smanjenim pritiskom. Filtrati su reducirani do suhog stanja pod smanjenim pritiskom. Rezultirajuća tvar triturirana sa 300ml metil t-butil eterom i izolirana filtriranjem. Ova tvar je ponovo otopljena u 300ml metanola i tretirana sa 0.5g drvenog ugljena, filtrirana a filtrat reduciran do suhog stanja pod smanjenim pritiskom. Tvar je ponovno razmrvljena u prah pod metil t-butil eterom, izolirana putem usisne filtracije i isprana sa eterom, i konačno heksanima. Tvar je vakuumski osušena da bi dala 22.6g svijetlo žuto smeđeg praha. The reaction was slowly quenched with 2 L of ice-cold water containing [17.88 g; 1134.1 mM] sodium thiosulfate with vigorous stirring for approximately 30 minutes at room temperature. The aqueous layer was then extracted with 6x200ml ethyl acetate before the aqueous layer was poured onto [259.8g;3.08M] sodium hydrogen carbonate containing 300ml n-butanol. The phases were separated and aqueous extracted with 4x250ml of n-butanol. The organic fractions were combined and washed with 3x250ml of water and once with 250ml of saturated brine. The resulting organic phase was then reduced to dryness under reduced pressure. The residue was suspended in methanol (~600ml) and anhydrous HCl gas was introduced into this mixture until a solution appeared. This solution was reduced to dryness under reduced pressure. The filtrates were reduced to dryness under reduced pressure. The resulting substance was triturated with 300 ml of methyl t-butyl ether and isolated by filtration. This substance was re-dissolved in 300 ml of methanol and treated with 0.5 g of charcoal, filtered and the filtrate was reduced to dryness under reduced pressure. The substance was triturated again under methyl t-butyl ether, isolated by suction filtration and washed with ether, and finally with hexanes. The substance was vacuum dried to give 22.6g of a light yellow brown powder.
Općeniti Postupak Za Pripremanje 9-Alkinil Minociklin Spojeva General Procedure for the Preparation of 9-Alkynyl Minocycline Compounds
1 mmol 9-jodo minociklina, 50mg tetrakis tripenilfosfinato palladata, 12 mg paladium acetata, 32mg bakar (I) jodida su otopljeni/suspenzirani u 10ml acetonitrila. Dodano je 2 do 5ml trietilamina i 3 do 5 mmol alkinil derivata. Reakcijska smjesa je snažno miješana između sobne temperature i 70 ̊C. Vrijeme reakcije je 2-24 sata. Kada je reakcija završena tamna suspenzija se filtrira pomoću celitne stelje i koncentrira. Sirov produkt se pročiščava pomoću preparativnog HPLC-a. Udružene frakcije su koncentrirane i uvedene u ~1ml metanola. Doda se ~3ml metanola zasićenog sa HCl, i produkt se istaloži sa eterom. 1 mmol of 9-iodo minocycline, 50 mg of tetrakis tripenylphosphinato palladate, 12 mg of palladium acetate, 32 mg of copper (I) iodide were dissolved/suspended in 10 ml of acetonitrile. 2 to 5 ml of triethylamine and 3 to 5 mmol of alkynyl derivative were added. The reaction mixture was vigorously stirred between room temperature and 70 ̊C. The reaction time is 2-24 hours. When the reaction is complete, the dark suspension is filtered using a celite pad and concentrated. The crude product is purified using preparative HPLC. The combined fractions were concentrated and introduced into ~1 ml of methanol. Add ~3ml of methanol saturated with HCl, and the product is precipitated with ether.
Općeniti Postupak Za Pripremanje 9-Aril Minociklin Spojeva General Procedure for the Preparation of 9-Aryl Minocycline Compounds
0.15mmol 9-jodominociklina, PdOAc (3.2mg), 229μl 2M Na2CO3 i 2 ekvivalenta fenil borne kieline su otopljeni/suspenzirani u 10ml metanola. Kroz reakcijsku tikvicu je protjeran argon a reakcija se odvija kroz najmanje četiri sata ili dok HPLC promatranje pokaže potrošnju početne tvari i/ili pojavljivanje produkata. Suspenzija se filtrira pomoću celita, a subjekt pročiščavanjem pomoću preparativnog HPLC na divinilbenzen koloni. 0.15mmol of 9-iodominocycline, PdOAc (3.2mg), 229μl of 2M Na2CO3 and 2 equivalents of phenyl boronic acid were dissolved/suspended in 10ml of methanol. Argon is expelled through the reaction flask and the reaction takes place for at least four hours or until HPLC observation shows the consumption of the starting substance and/or the appearance of products. The suspension is filtered using celite, and the subject is purified using preparative HPLC on a divinylbenzene column.
Spoj OU (9-(4-Trifluorometoksifenilureido)-Metil Minociklin) Compound OU (9-(4-Trifluoromethoxyphenylureido)-Methyl Minocycline)
[image] [image]
SHEMA 7 SCHEME 7
U 3 ml dimetilformamida se dodalo 150 mg (0.25 mmol) 9-metil aminominocilin trihidroklorida i 67 ml (0.50 mmol) trietilamina na 25 °C. Miješajući, dodaje se 75 ml (0.50 mmol) 4-trifluorometoksifenilizocianat i rezultirajuća reakcijska smjesa se miješa dva sata na 25 °C . Reakcija se nadgleda pomoću analitičkog HPLC-a (4.6 x 50mm reverzna faza Luna C18 kolona, 5 minutni linearni gradient 1-100% B pufer, A pufer je bila voda sa 0.1% trifluoroacetilne kiseline, B pufer je bio acetonitril sa 0.1% trifluoroacetilne kiseline). Nakon dovršenja, reakcija je pomiješana sa 1 ml vode i pH prilagođenim na približno 2.0 sa koncentriranom HCl. Otopina je filtrirana a spoj pročišćen pomoću preparativnog HPLC-a. Prinos spoja OU je bio 64 mg (37% prinos). Čistoća spoja OU je bila 95% određena pomoću LCMS (M+1 = 690). 150 mg (0.25 mmol) of 9-methylaminominociline trihydrochloride and 67 ml (0.50 mmol) of triethylamine were added to 3 ml of dimethylformamide at 25 °C. With stirring, 75 ml (0.50 mmol) of 4-trifluoromethoxyphenylisocyanate was added and the resulting reaction mixture was stirred for two hours at 25 °C. The reaction is monitored using analytical HPLC (4.6 x 50mm reverse phase Luna C18 column, 5 minute linear gradient 1-100% B buffer, A buffer was water with 0.1% trifluoroacetyl acid, B buffer was acetonitrile with 0.1% trifluoroacetyl acid ). After completion, the reaction was mixed with 1 ml of water and the pH adjusted to approximately 2.0 with concentrated HCl. The solution was filtered and the compound was purified by preparative HPLC. The yield of compound OU was 64 mg (37% yield). The purity of compound OU was 95% determined by LCMS (M+1 = 690).
Spoj LA (9-(4’Karboksi fenil) Minociklin) Compound LA (9-(4'Carboxy phenyl) Minocycline)
[image] [image]
U čistu, suhu reakcijsku posudu, stavljena je 9-jodominociklinska [500mg; 0.762mmol]bis HCl sol, paladij (II) acetat [17.2mg; 0.076mmol] zajedno as 10ml reagens gradiranog metanola. Kroz otopinu je odmah propuštena, uz miješanje,struja plina argona kroz približno 5 minuta. Reakcijska posuda je stavljena na opadanje i u nju je dodano 2M kalij karbonat otopne [1.91ml; 3.81mmol], slijedeći sa otopinom p-karboksifenil borne kiseline[238.3mg; 1.53mmol] u 5ml reagensa DMF. Obje ove otopine su prethodno oslobođene plinova sa plinom argona kroz otprilike 5 minuta. Reakcija je grijana kroz 45 minuta, napredak je nadgledan preko reverznog faznog HPLC-a. Reakcija je usisno filtrirana kroz umetak diatomejske zemlje i umetak je ispran sa DMF-om. Filtrat je pod vakuumom reduciran do ulja i tretiran sa t-butilmetil eterom. Kruta tvar je pročiščena pomoću reverznog faznog HPLC-a na DVB koristeći gradient vode i metanol/acetonitrila koji sadrži 1.0% trifluoroacetilne kiseline. Produkt je potvrđen pomoću spektra mase: utvrđeno M+1 578.58; struktura je potkrepljena sa 1H NMR. In a clean, dry reaction vessel, 9-iodominocycline [500mg; 0.762mmol] bis HCl salt, palladium (II) acetate [17.2mg; 0.076mmol] together with 10ml reagent graded methanol. A stream of argon gas was immediately passed through the solution, with stirring, for approximately 5 minutes. The reaction vessel was set to decline and 2M potassium carbonate soluble [1.91ml; 3.81mmol], following with a solution of p-carboxyphenyl boric acid [238.3mg; 1.53mmol] in 5ml of DMF reagent. Both of these solutions were previously degassed with argon gas for approximately 5 minutes. The reaction was heated for 45 minutes, progress was monitored via reverse phase HPLC. The reaction was suction filtered through a pad of diatomaceous earth and the pad was washed with DMF. The filtrate was reduced to an oil under vacuum and treated with t-butylmethyl ether. The solid was purified by reverse phase HPLC on DVB using a gradient of water and methanol/acetonitrile containing 1.0% trifluoroacetyl acid. The product was confirmed by mass spectrum: determined M+1 578.58; the structure was confirmed by 1H NMR.
Primjer 2: Analiza In vitro Minimumalne Inhibitorne Koncentracije (MIC) Example 2: Analysis of In Vitro Minimum Inhibitory Concentration (MIC)
Slijedeća analiza je upotrebljena za određivanje efikasnosti minociklinskih spojeva protiv uobičajenih bakterija. 2 mg svakog spoja je otopljeno u 100 μl DMSO. Otopina je tada dodana u kation-usklađen Mueller Hinton bujon (CAMHB), što je rezultiralo sa konačnom koncentracijom spoja od 200 μg po ml. Otopine minociklinskih spojeva su razređene do 50 μl volumena, sa koncentracijom testiranog spoja od .098 μg/ml. Determinante optičke gustoće (OD) su napravljene iz svježih log-faznih bujonskih kultura testiranih sojeva. Razređenja su napravljena tako da se postigne konačna gustoća stanica od 1x106 CFU/ml. Pri OD=1, gustoća stanica za različite rodove bi trebala biti približno: The following analysis was used to determine the effectiveness of minocycline compounds against common bacteria. 2 mg of each compound was dissolved in 100 μl of DMSO. The solution was then added to cation-matched Mueller Hinton broth (CAMHB), resulting in a final compound concentration of 200 μg per ml. Solutions of minocycline compounds were diluted to a volume of 50 μl, with a concentration of the tested compound of .098 μg/ml. Optical density (OD) determinations were made from fresh log-phase broth cultures of the tested strains. Dilutions were made to achieve a final cell density of 1x106 CFU/ml. At OD=1, cell density for different genera should be approximately:
E. coli 1x109 CFU/ml E. coli 1x109 CFU/ml
S. aureus 5x108 CFU/ml S. aureus 5x108 CFU/ml
Enterococcus sp. 2.5x109 CFU/ml Enterococcus sp. 2.5x109 CFU/ml
50 μl suspenzije stanica je dodano svakom izvoru mikrotitriranih ploča. Konačna gustoća stanica bi trebala biti približno 5x105 CFU/ml. Ove ploče su inkubirane na 35 ̊C u inkubatoru sa sobnim zrakom kroz približno 18 sati. Ploče su očitavane sa čitačem za mikroploče i vizuelno pregledane kada je to bilo potrebno. MIC je definiran kao najniža koncentracija minociklinskog spoja koja inhibira rast. Spojevi iz izuma pokazuju dobru inhibiciju rasta. 50 μl of the cell suspension was added to each well of the microtiter plates. The final cell density should be approximately 5x105 CFU/ml. These plates were incubated at 35 ̊C in an incubator with room air for approximately 18 hours. Plates were read with a microplate reader and visually inspected when necessary. The MIC is defined as the lowest concentration of a minocycline compound that inhibits growth. The compounds of the invention show good growth inhibition.
U Tabeli 1, spojevi koji su dobri inhibitori rasta određene bakterije su označeni sa *, spojevi koji su vrlo dobri inhibitori određene bakterije su označeni sa **, a spojevi koji su bili naročito dobri inhibitori određene bakterije su označeni sa ***. In Table 1, compounds that are good inhibitors of the growth of a particular bacterium are marked with *, compounds that are very good inhibitors of a particular bacterium are marked with **, and compounds that were particularly good inhibitors of a particular bacterium are marked with ***.
EKVIVALENTI EQUIVALENTS
Stručnjaci u ovom području će prepoznati, ili će biti u mogućnosti ustvrditi koristeći rutinske eksperimente, brojne ekvivalente ovdje opisanim specifičnim postupcima. Takvi ekvivalenti se smatraju da su unutar dosega ovog izuma i pokriveni su slijedećim zahtjevima. Sadržaj svih referenci, patenata i patentnih prijava citiranih u ovoj prijavi su ovime uključeni referencom. Odgovarajuće komponente, procese, i metode tih patenata, prijava i drugih dokumenata mogu se odabrati za ovaj izum i njegove sastavne dijelove. Those skilled in the art will recognize, or be able to establish using routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims. The contents of all references, patents and patent applications cited in this application are hereby incorporated by reference. Appropriate components, processes, and methods of those patents, applications, and other documents may be selected for this invention and its constituent parts.
Claims (68)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20100060A HRP20100060A2 (en) | 2001-06-29 | 2010-02-01 | 9-substituted monocycline compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/020721 WO2002004406A2 (en) | 2000-07-07 | 2001-06-29 | 9-substituted minocycline compounds |
HR20100060A HRP20100060A2 (en) | 2001-06-29 | 2010-02-01 | 9-substituted monocycline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100060A2 true HRP20100060A2 (en) | 2010-03-31 |
Family
ID=42040850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100060A HRP20100060A2 (en) | 2001-06-29 | 2010-02-01 | 9-substituted monocycline compounds |
Country Status (1)
Country | Link |
---|---|
HR (1) | HRP20100060A2 (en) |
-
2010
- 2010-02-01 HR HR20100060A patent/HRP20100060A2/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030091A2 (en) | 9-substituted minocycline compounds | |
AU2008207359B2 (en) | 7,9-substituted tetracycline compounds | |
AU2001286388A1 (en) | 9-substituted minocycline compounds | |
EP1301466A2 (en) | 7-substituted tetracycline compounds | |
AU2001271642A1 (en) | 7-substituted tetracycline compounds | |
HRP20100060A2 (en) | 9-substituted monocycline compounds | |
AU2006201433A1 (en) | 7-Substituted tetracycline compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20130629 Year of fee payment: 13 |
|
OBST | Application withdrawn |